US20080021421A1 - Acupoint patch - Google Patents
Acupoint patch Download PDFInfo
- Publication number
- US20080021421A1 US20080021421A1 US11/831,588 US83158807A US2008021421A1 US 20080021421 A1 US20080021421 A1 US 20080021421A1 US 83158807 A US83158807 A US 83158807A US 2008021421 A1 US2008021421 A1 US 2008021421A1
- Authority
- US
- United States
- Prior art keywords
- acupoint
- group
- medical condition
- pain
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 claims abstract description 61
- 239000006049 herbal material Substances 0.000 claims abstract description 4
- 239000007933 dermal patch Substances 0.000 claims abstract 11
- 239000003814 drug Substances 0.000 claims description 68
- 210000005036 nerve Anatomy 0.000 claims description 39
- 230000017531 blood circulation Effects 0.000 claims description 29
- 241000723353 Chrysanthemum Species 0.000 claims description 23
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 23
- 210000003205 muscle Anatomy 0.000 claims description 15
- 208000002173 dizziness Diseases 0.000 claims description 14
- 201000001881 impotence Diseases 0.000 claims description 12
- 206010019233 Headaches Diseases 0.000 claims description 11
- 208000002193 Pain Diseases 0.000 claims description 11
- 231100000869 headache Toxicity 0.000 claims description 11
- 230000036407 pain Effects 0.000 claims description 11
- 208000019255 Menstrual disease Diseases 0.000 claims description 10
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 10
- 206010022437 insomnia Diseases 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 206010011224 Cough Diseases 0.000 claims description 8
- 206010041497 Spermatorrhoea Diseases 0.000 claims description 8
- 206010047700 Vomiting Diseases 0.000 claims description 8
- 230000008673 vomiting Effects 0.000 claims description 8
- 230000008961 swelling Effects 0.000 claims description 7
- 206010019705 Hepatic pain Diseases 0.000 claims description 6
- 208000019790 abdominal distention Diseases 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 241000112528 Ligusticum striatum Species 0.000 claims description 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 5
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 5
- 206010047513 Vision blurred Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 4
- 208000008967 Enuresis Diseases 0.000 claims description 4
- 206010019909 Hernia Diseases 0.000 claims description 4
- 206010050819 Musculoskeletal chest pain Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 4
- 201000007100 Pharyngitis Diseases 0.000 claims description 4
- 230000001815 facial effect Effects 0.000 claims description 4
- 241000928504 Centipeda minima Species 0.000 claims description 3
- 241000935235 Fritillaria meleagris Species 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 241000218378 Magnolia Species 0.000 claims description 3
- 244000179560 Prunella vulgaris Species 0.000 claims description 3
- 240000006079 Schisandra chinensis Species 0.000 claims description 3
- 240000000377 Tussilago farfara Species 0.000 claims description 3
- 235000004869 Tussilago farfara Nutrition 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 230000004379 myopia Effects 0.000 claims description 3
- 208000001491 myopia Diseases 0.000 claims description 3
- 235000008113 selfheal Nutrition 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010000060 Abdominal distension Diseases 0.000 claims description 2
- 201000000736 Amenorrhea Diseases 0.000 claims description 2
- 206010001928 Amenorrhoea Diseases 0.000 claims description 2
- 206010002653 Anosmia Diseases 0.000 claims description 2
- 206010002953 Aphonia Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010011878 Deafness Diseases 0.000 claims description 2
- 206010013789 Dry throat Diseases 0.000 claims description 2
- 206010015958 Eye pain Diseases 0.000 claims description 2
- 208000033830 Hot Flashes Diseases 0.000 claims description 2
- 206010060800 Hot flush Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 206010028735 Nasal congestion Diseases 0.000 claims description 2
- 208000001140 Night Blindness Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 206010067171 Regurgitation Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 231100000540 amenorrhea Toxicity 0.000 claims description 2
- 235000019558 anosmia Nutrition 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 231100000895 deafness Toxicity 0.000 claims description 2
- SZGZILRQIYNODJ-UHFFFAOYSA-L disodium;7,12-dihydroquinoxalino[3,2-b]phenazine-2,9-disulfonate Chemical group [Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2N=C(C=C3C(NC4=CC=C(C=C4N3)S(=O)(=O)[O-])=C3)C3=NC2=C1 SZGZILRQIYNODJ-UHFFFAOYSA-L 0.000 claims description 2
- 201000006549 dyspepsia Diseases 0.000 claims description 2
- 210000001061 forehead Anatomy 0.000 claims description 2
- 208000016354 hearing loss disease Diseases 0.000 claims description 2
- 230000007803 itching Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 230000002969 morbid Effects 0.000 claims description 2
- 206010029410 night sweats Diseases 0.000 claims description 2
- 230000036565 night sweats Effects 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 241000218691 Cupressaceae Species 0.000 claims 2
- 206010013990 dysuria Diseases 0.000 claims 1
- 230000008855 peristalsis Effects 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 22
- 238000001467 acupuncture Methods 0.000 description 63
- 230000000694 effects Effects 0.000 description 42
- 230000001105 regulatory effect Effects 0.000 description 35
- 210000001367 artery Anatomy 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 25
- 239000008280 blood Substances 0.000 description 25
- 229940079593 drug Drugs 0.000 description 23
- 241000244355 Ligusticum Species 0.000 description 21
- 239000010410 layer Substances 0.000 description 21
- 241001072909 Salvia Species 0.000 description 19
- 235000017276 Salvia Nutrition 0.000 description 19
- 210000004204 blood vessel Anatomy 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 230000006870 function Effects 0.000 description 19
- 210000003462 vein Anatomy 0.000 description 19
- 241000544270 Angelica acutiloba Species 0.000 description 17
- 238000013270 controlled release Methods 0.000 description 17
- 235000008216 herbs Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 230000004089 microcirculation Effects 0.000 description 14
- 235000015097 nutrients Nutrition 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 230000008901 benefit Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 8
- 239000000686 essence Substances 0.000 description 8
- 230000003601 intercostal effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 229920003023 plastic Polymers 0.000 description 7
- 239000004033 plastic Substances 0.000 description 7
- 230000004936 stimulating effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 230000004087 circulation Effects 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 230000002040 relaxant effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 5
- 208000003464 asthenopia Diseases 0.000 description 5
- 230000008344 brain blood flow Effects 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000000599 controlled substance Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000015654 memory Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000135309 Processus Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 239000002956 ash Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003889 eye drop Substances 0.000 description 4
- 229940012356 eye drops Drugs 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 229910001385 heavy metal Inorganic materials 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000012676 herbal extract Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 210000001937 intercostal nerve Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003448 thoracic nerve Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 230000004436 pseudomyopia Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007790 scraping Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 206010073753 Fear of injection Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 235000016838 Pomo dAdamo Nutrition 0.000 description 1
- 244000003138 Pomo dAdamo Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002168 brachiocephalic trunk Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000269 carotid artery external Anatomy 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007247 enzymatic mechanism Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001664 manubrium Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- -1 nitrogen ketone Chemical class 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000002589 oculomotor nerve Anatomy 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NCTHNHPAQAVBEB-WGCWOXMQSA-M sodium ferulate Chemical compound [Na+].COC1=CC(\C=C\C([O-])=O)=CC=C1O NCTHNHPAQAVBEB-WGCWOXMQSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/023—Adhesive plasters or dressings wound covering film layers without a fluid handling layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00446—Plasters use for oriental medicine
Definitions
- the present invention relates to herbal medicine and more particularly relates to therapeutic patches which are applied to various locations of a patient for therapeutic purposes.
- the essences of natural herbs are extracted to make therapeutic patches of the present invention, based on the principles of Chinese medicine and acupuncture.
- the patches of the present invention can achieve an effect similar to, and yet better than, that of acupuncture.
- the patches of the present invention can relax muscles, nerves and blood vessels around the eyes through painless and easy application. They also help alleviate eye fatigue and give the patient better vision.
- Acupuncture with a history dating all the way back to several thousand years in China, is now widely recognized in western medical field.
- scientists have done researches as well as anatomic, histochemical, and algesia physiologic experiments based on contemporary medical knowledge while continuing the development of acupuncture.
- Phenomena and the nature of the main and collateral channels have been studied from different perspectives. Issues such as the connection between acupuncture points and feelings, as well as that of acupuncture points and body organs have been researched to promote the benefits of combining acupuncture and contemporary medical science.
- acupuncture has been a focus of the international medical field. It is known to all that acupuncture cures diseases by stimulating specific locations, namely acupoints, of the body. Why is acupuncture applied to acupoints, instead of other parts of the body?
- a brief introduction is as follows.
- acupoint energy substance is a cytology and biochemistry issue. Recent research indicates that main and collateral acupoints are points consisting of cells containing a relatively large amount of adenosine triphosphate (ATP). Adenosine is the factory that generates power for the cells. It contains abundant ATP synthetic enzyme and is capable of producing a large amount of ATP energy. During experiments, tissue cells taken from such acupoints such as Zusanli, Hegu and Quchi, as well as from non-acupoint locations were dyed and observed under microscope. Comparison indicated that the adenosine inside these cells increased and showed no deformity.
- ATP adenosine triphosphate
- Stimulating acupoints resulted in the secretion of active substances and enhanced the bridging function of 29 KD protein.
- the amount of information passing through the channels increased, resulting in strong interactive stress and achieving internal balance.
- 29 KD protein transmits more than just biological electrical signals. It can also transmit a variety of ion substances or small molecule substance. This kind of transmission is completed through continuous transmission by 29 KD protein. This is the mechanism underlying the effect of stimulating channels and acupoints.
- Acupuncture has a history of over three thousand years in China. Over three thousand years ago, Chinese doctors started to cure different diseases with acupuncture. Recently, acupuncture has been widely used to treat eye diseases and ailments. The mechanism of alleviating and curing eye diseases involves regulating the channels and the vegetative nervous system. Then observation is on the artery peripheral plexus and the capillary artery front plexus formed by adrenalinergic nerves and cholinergic nerves around the small blood vessels distributed at certain acupoints with fluorescence organ chemical method. Experimental morphology proved that they were all fibers of sympathetic ganglions with the functions of controlling peripheral circulation resistance and local blood circulation.
- cholesterase small nerve tracts consisting of the primitive marrow fiber inside the axiom nerve branches penetrated to deep underneath the acupoints, and extended to close to the capillary artery along to the small artery and vein before forming free ends. They then joined the capillary wall nerves and the vegetative nerves. Therefore, sympathetic nerves are considered an important part of the channels.
- Acupuncture cures eye diseases by stimulating acupoints around the eyes and adjusting functions of the vegetative nerves. Microcirculation is promoted, and so is oxygen and nutrients transmission around the eye acupoints. Microcirculation stasis is alleviated, and the ancillary muscles around the eyes are regulated and relaxed. This results in complete regulation and adjustment of the eyes. In the meantime, it also helps reduce tension of the cerebral cortex and thus achieves relaxation, as well as improving sleep and memory.
- Acupuncture has represented an essential part of traditional Chinese medicine. Its healing powers and effects have been widely recognized. We all know that in acupuncture, needles are used to stimulate acupoints for promoting blood circulation and relaxing nerves and muscles. Therefore, many ailments, discomforts or sicknesses can be cured with acupuncture therapy. Many people have become aware that acupuncture has an advantage in relieving pains and regulating immunity that is not matched by western medicines. However, acupuncture has its disadvantages too. First, although they are aware of the benefits of acupuncture, many people refuse to accept it as a therapy because of their phobia of pain, namely from the needles. Unable to overcome the fear of needles, they have no choice but to avoid acupuncture altogether.
- a method of using acupoint patches, an apparatus and a method of making acupoint patches is disclosed.
- the acupoint patch of the present invention uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. It originates from acupuncture but easily surpasses acupuncture. As the essence of traditional Chinese medicine, acupuncture has been studied and developed during recent years to achieve better effects and minimum side effects. Acupoint patch application in accordance with the present invention now reaches beyond what acupuncture therapy can deliver.
- the acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture. As previously mentioned, acupuncture can only relax ciliary muscles (effective on pseudomyopia) and only has a temporary effect. The reason is because in acupuncture, the needles only stay for 20-30 minutes. In about two hours after the treatment finishes, the effect of acupuncture starts to diminish. The successful experiment of the acupoint patch of the present invention has overcome the problem of the temporary effect of acupuncture therapy. It is also the first painless therapy. Patients only need to apply the acupoint patch of the present invention to designated acupoints on the face (Zanzhu, temple, Sibai) before bedtime to achieve the desired results.
- the acupoint patch of the present invention is easy and safe. It is suitable for patients of different ages.
- the acupoint patch of the present invention not only has the transdermal absorption feature of traditional plasters, but also uses controlled release technologies so that the herbal nutrients enter blood circulation at an even speed, to ensure consistent blood medicine concentration and to avoid blood medicine concentration peak/trough problem.
- FIG. 1 illustrates the blood medicine concentration (in ng/ml) vs. application time (in hour).
- FIG. 2 illustrates blood medicine concentration with peak and trough phenomenon.
- FIG. 3 shows steady blood medicine concentration over time, where the treatment zone is more stabilized.
- FIG. 4 illustrates a comparison of the acupoint patch of the present invention and other products in terms of blood medicine concentration vs. time.
- FIG. 5 illustrates an exemplary flow chart for the herbal extraction process in accordance with the present invention.
- a method, apparatus and method of making medicated patches is disclosed.
- numerous terminology in herbal medicine, acupuncture and acupoints will be referenced, using terms familiar to those skilled in the art.
- the phrase “acupoint patch” and Applicant's trademark “OCULAXTM” are used interchangeably in the present application, as they both refer to the transdermal acupoint patches for the controlled release of herbal extracts through the acupoints of a patient's body.
- Transdermal medicine has been used in therapies as early as in the ancient times.
- Traditional Chinese plasters are some of the examples. Plasters help overcome the problems of pain and time limitation of acupuncture. However, the effect of plasters is less desirable than that of acupuncture, due to their limited permeability.
- traditional plasters do have some of the characteristics of transdermal patches, the dosages are usually not precise. Precise control and maintenance of the desired blood medicine concentration are difficult to achieve, thus resulting in unbalanced blood medicine concentration (concentration peaks and lows). That is to say, during the first two hours after plasters are applied, the amount of medicine entering blood circulation is higher than the required amount, whereas after two hours, the amount of medicine entering blood circulation becomes insufficient.
- FIG. 1 illustrates the blood medicine concentration (in ng/ml) vs. application time (in hour).
- the acupoint patch of the present invention uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. It originates from acupuncture but easily surpasses acupuncture. As the essence of traditional Chinese medicine, acupuncture has been studied and developed during recent years to achieve better effects and minimum side effects. Acupoint patch application in accordance with the present invention now reaches beyond what acupuncture therapy can deliver.
- the acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture. As previously mentioned, acupuncture can only relax ciliary muscles (effective on pseudomyopia) and only has a temporary effect. The reason is because in acupuncture, the needles only stay for 20-30 minutes. In about two hours after the treatment finishes, the effect of acupuncture starts to diminish. The successful experiment of the acupoint patch of the present invention has overcome the problem of the temporary effect of acupuncture therapy. It is also the first painless therapy. Patients only need to apply the acupoint patch of the present invention to designated acupoints on the face (Zanzhu, temple, Sibai) before bedtime to achieve the desired results.
- the acupoint patch of the present invention is easy and safe. It is suitable for patients of different ages.
- the acupoint patch of the present invention not only has the transdermal absorption feature of traditional plasters, but also uses controlled release technologies so that the herbal nutrients enter blood circulation at an even speed, to ensure consistent blood medicine concentration and to avoid blood medicine concentration peak/trough problem.
- the acupoint patch of the present invention is made of pure, natural herb extracts by combining traditional Chinese acupuncture and contemporary transdermal absorption controlled-release technologies.
- the acupoint patch in accordance with the present invention is a product with the following important implementation features:
- D It is a multi-layer, e.g. five-layer patch.
- Patch application acupoints include Zanzhu, temple, Sibai, Fengchi, Jingming, Touwei, Yinxiang, Yingtang, Yifeng and Anmian;
- the acupoint patch is applied to the designated acupoints before bed time and taken off the following morning.
- the application time is 6-8 hours.
- the acupoint patch can be applied at any time without causing any pain.
- Raw materials include pure natural herbs such as Tangkuei ( Angelica sinensis ), Ligusticum ( Ligusticum wallichii ), chrysanthemum, and Salvia root ( Salvia miltiorrhiza ). These ingredients have no side effect of whatsoever. Tangkuei, Ligusticum, chrysanthemum and Salvia root can all promote blood circulation, regulate nervous system and reduce muscle spasm.
- Acupoint patch helps achieve all the benefits of painless acupoint therapy.
- the unique characteristics of the acupoint patch of the present invention are attributable to the fact that it is the combination of traditional Chinese acupuncture and modern technologies. It follows both the principles of traditional Chinese acupuncture—applying natural herbs at acupoints—and combines modern transdermal absorption controlled-release technologies. As a result, Oculax can release effective ingredients at the acupoints consistently for a relatively longer period of time, and thus, regulate the nerves, muscles, and blood vessels around the eyes and in the head to promote eye and head blood circulation and to achieve the goal of relaxation. It helps in different types of eye problems, such as dry eyes, eye fatigue, vision deterioration, photaesthesia and tearing, myopia, presbyopia, glaucoma, and cataract. It also alleviates migraine, dizziness and insomnia. It is the textbook example of combining Chinese medicine with western medicine. OCULAXTM has surpassed conventional oral medicines or eye drops and opened up a new era for eye maintenance products.
- the acupoint patch of the present invention may be made of natural herbs such as Ligusticum, Tangkuei, Salvia root, and chrysanthemum. Records in pharmacopoeia, e.g. ZUENG Hu-Zhan et. al, MODERN STUDY OF TRADITIONAL CHINESE MEDICINE, Vol. 1-6, Xue Yuan Press, Beijing, China, 1999, ISBN 7-5077-1320-2, indicate that they have the following functions:
- Ligusticum Provides blood and Qi circulation. Ligusticum can remarkably increase brain blood flow and improve mater microcirculation and flow. It has an evident effect in alleviating chronic microcirculation disturbance, especially bulbar conjunctiva microcirculation disturbance.
- Salvia Root Provide blood and Qi circulation, remove blood stasis and alleviate pain, promote micro blood circulation. It has a remarkable effect in improving microcirculation, especially eye bulbar conjunctiva microcirculation.
- Salvia root extract can remarkably dilate the capillaries of rabbits with microcirculation disturbance.
- rabbits that had been given intravenous injections of 10% macromolecule dextrose were given Salvia root extract.
- the effect of Salvia root extract on the capillaries and plasma lactic acid content was observed.
- Salvia root has an anti-aging function.
- Scholars have compared the effects of Salvia root and vitamin E on the SOD and LPO of aged rats.
- the effects of Salvia root are better than those of vitamin E.
- Salvia root also remarkably lowered the content of peroxide fat in the serum, heart, liver and kidney of the same aged rats (P ⁇ 0.01).
- Compared with vitamin E, Salvia root has better effects.
- Tangkuei Promote blood and Qi circulation. Major results include improved flow, faster flow speed and improvement of fundus blood circulation. Experiments and research has indicated that Tangkuei is the ideal ingredient to regulate blood vessel functions. Tangkuei can dilate peripheral blood vessels, lower blood resistance, and improve blood circulation. Experiments have shown that Buerger's disease patients experienced improvement of blood circulation after one month of Tangkuei injection. The effective rate is 60%.
- Chrysanthemum Improve vision and refresh, eliminate wind and clear heat. It can be used to treat red eyes, swelling and pain, headache and insomnia, and blurred vision and dizziness. It can dilate blood vessels, increase blood flow and delay the aging process.
- chrysanthemum injection can dilate blood vessels and increase blood flow.
- Thoracic sedated cats were given intravenous injection of 1.5-2.0 g/kg of chrysanthemum.
- Coronary venous sinus flow was increased by 93% immediately.
- the coronary flow was increased as compared to that before the injection.
- the coronary flow was increased by 61% and 53% respectively in one minute and three minutes after application of medicine as compared to that before the application.
- Chrysanthemum injection can also remarkably dilate skin and organ blood vessels. Based on this, chrysanthemum is used in OCULAXTM to improve blood circulation and to increase oxygen and nutrients supplied to the eyes and the brain blood vessels.
- the above natural herbs have no side effects.
- the natural nutrients can enter blood circulation through the skin to relax nerves, blood vessels and muscles around the eyes and to alleviate eye fatigue. They can promote brain blood circulation, help in sleep and improve memory.
- the acupoint patch of the present invention is a patch made of natural herbs using transdermal absorption method. It is directly applied to acupoints around the eyes and features characteristics not possessed by oral medicines or eye drops.
- the acupoint patch of the present invention has five layers with different natures and functions, as will be described below:
- LINING LAYER Impermeable to medicines, provide protection and supporting functions.
- CONTROLLED RELEASE LAYER Serves to control and release medicines at the required speed.
- PRESSURE SENSITIVE LAYER Attaching the acupoint patch to the skin can provide an explosive dosage of medicine so that medicines can saturate the cuticle quickly and enter into body blood circulation.
- PROTECTION AND NON-STICKING LAYER Remove this layer, before applying the acupoint patch to the patient's acupoint(s).
- the acupoint patch is a round patch with one side coated with self-adhesive medicine film. Each patch is 2.27 square centimeters.
- Each set consists of six round patches attached to 4 ⁇ 7 centimeter non-sticking plastic protection film. Each patch is a dark brown patch. Even medicine layer of consistent color should be observed in any indoor location without direct sunlight. There should be no detachment of the medicine layer. The plastic side should be even, clean and free from areas not covered by medicines.
- INGREDIENTS The main ingredients of each set of patches include Ligusticum, Salvia root, Tangkuei and chrysanthemum. Other materials used include polyacrylic acid medical pressure-sensitive glue and polyester lining film.
- FUNCTIONALITY Relax nerves and muscles, refresh, alleviate fatigue, promote blood and Qi circulation, and distribute and minimize body heat.
- Weight variance Take three sets of patches (total 18 pieces). Remove patches from the adhesive layer. Weigh each piece with 1/10000 balance and calculate the average weight. Compare the weight of each piece. The number of patches with a weight variance over +5% shall not exceed two. No weight variance exceeding +10% is allowed.
- Area of the patch Take five patches. Measure the diameter of each round patch and calculate the area. The area of each set may not be less than 2.2 square centimeters (the sum of six patches.)
- the acupoint patches of the present invention can achieve consistent application of medicines. Medicines released at a controlled speed enter body circulation consistently and steadily. This helps avoid peak/trough blood medicine concentrations of other medicine application methods and gives full play to the curative and regulating functions of the medicines. Since the medicines do not pass the digestive tract, destruction of the natural herb ingredients by pH, food and digestive fluids is avoided. Intestine or stomach upset, poor absorption and side effects of the metabolites due to stimulation of the digestive tract are also avoided. In addition to controlling medicine release, patients may also apply OCULAXTM based on their conditions.
- FIG. 2 shows blood medicine concentration with peak and trough phenomenon.
- FIG. 3 shows steady blood medicine concentration over time, where the treatment zone is more stabilized.
- the acupoint patch of the present invention brings out the curing effects of short biological half-life medicines that cannot be easily applied through oral taking or injection, as well as medicines with narrow “treatment window”, while limiting their side effects.
- the preliminary filtering function of the liver is bypassed to avoid dissolution of medicines by the liver and damage to the liver caused by medicines.
- the acupoint patch of the present invention is easy to use. It can be applied or removed based on the patient's need. It is painless and easily accepted by the patients.
- the acupoint patch can regulate eye nerves, blood vessels and muscles to restore normal eye operation.
- transdermal controlled medicine release helps achieve predetermined and longer medicine effective time, and improves medicine's effectiveness.
- OCULAXTM achieves satisfactory results without causing any side effects through transdermal absorption at acupoints.
- the frequency of medication and total dosage are reduced whereas the effectiveness is improved. This is the optimal eye care product.
- the patches of the present invention should be applied to three sets of acupoints around the eyes every night.
- the blood vessels, nerves and muscles passing these three sets of acupoints are introduced as follows:
- ZANZHU This acupoint is located at the side above the eyebrows at the corner of the eye sockets. Distributed at this acupoint are frontal artery, vein and the medial lateral branches of facies frontalis.
- TEMPLE This acupoint is located 0.5 centimeter from the tip of the brow. Distributed at this acupoint are the temporal branches of nervus facialis, and orbital arteries and veins.
- SIBAI This acupoint is below the pupil at the inferior orbital socket. Distributed at this acupoint are branches of facial arteries and veins. Orbita arteries and veins are distributed around nervus facialis and inferior orbital nerves.
- the acupoint patch of the present invention thus helps in absorption of natural herbal nutrients by using acupoint patch mechanism.
- the acupoint patch of the present invention works via the nerve-incretion-immunity system as follows:
- the acupoint patch of the present invention uses natural herb extracts as raw materials. It is made based on the mechanism of acupuncture and contemporary transdermal controlled medicine release technologies. With the advantages of the acupoints and the transdermal controlled medicine release, OCULAXTM can release medicines into blood vessels, nerves and muscles around the eyes in a short time without the pain of acupuncture. It saves time and improves vision-regulating effectiveness. OCULAXTM is truly an acupuncture therapy without needles.
- OCULAXTM application instructions Apply OCULAXTM to the six designated acupoints (two on Zanzhu, two on the temples and two on Sibai) every night before sleep. OCULAXTM stays for 6-8 hours. During these 6-8 hours, the natural herb nutrients enter blood circulation directly through the acupoints at an even speed. The result is much better than that of 30 minutes of traditional acupuncture. It also solves the problem of short needle-staying time.
- OCULAXTM can promote local and general blood circulation, enhance metabolism, and improve local nutrition, cell immune and fluid immune functions.
- FIG. 4 illustrates a comparison of OCULAXTM and other products in terms of blood medicine concentration vs. time.
- Curve A represents oral medication
- Curve B represents acupuncture
- Curve C represents OCULAXTM. From the above figure we can tell that compared with oral medicines and acupuncture, OCULAXTM has a longer and more stable regulating function.
- the herbal nutrient content of 6 pieces of OCULAXTM is 60 mg, 40% of which enters blood circulation after released through the skin. This means that approximately 24 mgs work on the eyes. The effect can last 6-8 hours. Among the 60 mg nutrients of oral medicines, 25% is absorbed by the body and only 10-20%, e.g. 1.5-3 mg work on the eyes. The effects can last 2-3 hours. The effect of acupuncture is highly desirable in a short period of time. But the effects only last for this short period of time. The effective time is only 15-20% of that of OCULAXTM.
- Acupoint patches using transdermal controlled medicine release present a novel method of treating other ailments and illness.
- such acupoint patches can also be used at other acupoints to treat other illness, provided that they are applied with the proper herbal extracts.
- Acupoints that can regulate and relax eyes Zanzhu, temple, Sibai, Jingming, Fengchi
- Acupoints that can regulate sleep patterns Anmian, Fengchi, Yifeng, temple
- Acupoints that can regulate the lungs and the tracheas Feiyu, Tiantu, Dingchuan, Shenyu
- Acupoints that can regulate liver metabolism Qimen, Riyue, Zhangme, Zhongwan, Ganyu, Piyu
- Acupoints that can alleviate nasal allergy Yingxiang, Feiyu, Yintang, Dazhui, Bitong
- Acupoints that can regulate blood pressure Yintang, Renyin, Fengehi, Yifeng, Dazhui
- Acupoints that can regulate sexual functions Qihai, Kaiyuan, Zhongji, Qugu, Qichong, Guilai
- Acupoints that can treat dementia Touwei, temple, Fengchi, Yifeng, Yintang
- Yinxiang Located at the muffle at the same level as the medial point of the outer edge of ala nasi. Passing this acupoint include facial artery and vein branches, as well as branches of nervus facialis and orbital nerves. Regulating this acupoint can alleviate nasal congestion, anosmia, nose bleeding, running nose, facial itching and swelling.
- Yintang Located in the middle point between the two brows. Regulating this acupoint can alleviate headache, carebaria, forehead pain and insomnia.
- Fengchi Located at the pit above sternocleidomastoid. Passing this acupoint include branches of occipital arteries and veins and branches of occipital nervelets. Regulating this acupoint can alleviate headache, insomnia, blurred vision and glaucoma.
- Yifeng Behind the earlobe at the pit between the lower jaw and the permite mastoideus. Passing this acupoint include ear arteries and veins, and ear major nerves. At the deeper level is the nervus facialis node permite mastoideus. Regulating this acupoint can alleviate tinnitus, deafness and blurred vision.
- Anmian Located at the middle point between Yifeng and Fengchi. Regulating this acupoint can alleviate insomnia, dizziness, headache and palpitation.
- Dazhui Located below the permite mastoideus of vertebrae cervicales VII, at the same level as the shoulder. Passing this acupoint include branches of carotid arteries, the back branches of cervical nerve VIII, and the median part of the back branches of thoracic nerve 1. Regulating this acupoint can alleviate headache, coughing and panting.
- Dingchuan Located next to Dazhui. Passing these acupoints are the same nerves and blood vessels as those passing Dazhui. Regulating this acupoint can cure asthma and alleviate coughing.
- Jingming Located at the pit above eye corner. Passing this acupoint include inner canthus arteries and veins. At the deeper level are main branches of eye arteries and veins. Passing this acupoint also include upper and lower trochlea nerves. At the deeper level are oculomotor nerves and rock nerves. Regulating this acupoint alleviates tearing, nyctalopia, dizziness, myopia and eye pain.
- Qimen Located below the nipple between ribs VI. Passing this acupoint include intercostal arteries and veins (VI), and intercostal nerves (VI). Regulating this acupoint can alleviate liver pain, abdominal distension, sour regurgitation.
- Riyue Located one rib below Qimen and the nipple between ribs VII. Passing this acupoint include intercostal arteries and veins (VII), and intercostal nerves (VII). Regulating this acupoint can cure choleplania, liver diseases, rib pain and vomiting.
- Zhangmen Located at the side of abdomen below the tip of floating rib XI. Passing this acupoint include end of intercostal arteries (X) and below it is intercostals nerves (X). Regulating this acupoint can alleviate liver pain, abdominal distention, vomiting, indigestion and diarrhea.
- Zhongwan Located on the median of the abdomen, four inches above the navel. Passing this acupoint include arteria epigastrica and vena superior, and the front branches of intercostals nerves (VII). Regulating this acupoint can cure choleplania, liver pain, stomachache, abdominal distention, reduce peristaltic sound, and alleviate vomiting and insomnia.
- VIP intercostals nerves
- Feiyu Located below the permite mastoideus of thoracic vertebra m, 1.5 inches next to Shenzhu (GV12). Passing acupoint include the inner back branches of intercostals arteries and veins. At the deeper level are outer branches. Regulating this acupoint can reduce coughing, panting, chest pain, night sweat, and hot flash.
- Ganyu Located below the crest of thoracic vertebra IX, 1.5 inches next to Jinsuo (GV8). Passing this acupoint include the inner back branches of intercostals arteries and veins, the inner back branches of thoracic nerves IX and X. At the deeper level are the outer branches. Regulating this acupoint can cure choleplania, rib pain, dizziness and back pain.
- Piyu Located below the crest of thoracic vertebra XI, 1.5 inches next to Jizhong. Passing this acupoint include the back branches of intercostal arteries and veins, thoracic nerves XI and XII, the inner back branches. At the deeper level are the outer branches. Regulating this acupoint can alleviate stomachache, choleplania, abdominal distention, vomiting and dropsy.
- Shenyu Located below the crest of lumbar vertebra, 1.5 inches next to Mingmen. Passing this acupoint include the back branches of loin arteries and veins (II), and the outer back branches of loin nerves. At the deeper level are the outer branches. Regulating this acupoint can alleviate dizziness, asthma, dropsy and lower back pain.
- Tiantu Located on the medial point above the sternum. Passing this acupoint include the branches of subcutaneous arteria carotis, thyroid arteries. At the deeper level are tracheas. Behind the manubrium are innominate arteries and aorta. Passing acupoint also include the front branches of supraclavian nerves. Regulating this acupoint can reduce asthma, coughing, sore and swelling throat, aphonia and dry throat.
- Yongquan Located on the pelma at the pit when toes are flexed, near the cross point of the front 1 ⁇ 3 and the back 2 ⁇ 3 of the pelma. Passing this acupoint include deeper arcus plantaris and musculus nerves. Regulating this acupoint can alleviate headache, dizziness, sore throat, dry tongue, hypertension and constipation.
- Zhongji Located on the median of the abdomen, four inches below the navel. Passing this acupoint include branches of superficial napes arteries and veins, the branches of arteria epigastrica and vena inferior, and branches of femoris hypogastric nerves. Regulating this acupoint can cure impotence, frequent micturiction, spermatorrhea, female sexual coldness, morbid leucorrhoea, and menstrual disorder.
- Kaiyuan Located on the median of the abdomen, three inches below the navel. Blood vessels passing this acupoint are the same as those passing Zhong Ji. Passing acupoint include the front inner branches of intercostal nerves XII. Regulating this acupoint can cure spermatorrhea, enuresis, impotence, difficult urination, and menorrhalgia.
- Qugu Located at the middle point of the upper edge of symphysis pubis. Passing this acupoint include branches of arteria epigastrica inferior, obturator arteries, and branches of femoris hypogastric nerves. Regulating this acupoint can cure spermatorrhea, impotence, enuresis, menorrhalgia, and menstrual disorder.
- Qihai Located on the median of the abdomen, 1.5 inches below the navel.
- the blood vessels and nerves passing this acupoint are the same as those passing Shimen. Regulating this acupoint can cure impotence, hernia, spermatorrhea, diarrhea, amenorrhea and menstrual disorder.
- Guilai Located at four inches below the navel and two inches next to Zhongji. Passing this acupoint include arteria epigastrica and vena inferior as well as femoris hypogastric nerves. Regulating this acupoint can alleviate abdominal pain, and cure impotence, hernia and menstrual disorder.
- Qichong Located at five inches below the navel and two inches next to Qugu. Passing this acupoint include superficial branches of napes arteries and veins and at the outer side are arteria epigastrica and vena. Passing this acupoint are also iliac nerves. Regulating this acupoint can cure impotence, vulva swelling, menorrhalgia and menstrual disorder.
- These patches are the same as that of OCULAXTM. They are also made of natural herb extracts by combining acupuncture and transdermal controlled release technologies.
- Chinese herbs used include tussilago farfara , perillaseed, tendril-leaved fritillary bulb, fruit of Chinese magnoliavine, fructus ligustri lucidi, golden cypress, Centipeda minima , magnolia flower, radix angelicae formosanae, selfheal, radix achyranthis bidentatae and ramulus uncariae rhynchophyllae.
- the patches are to designated acupoints based on their different functions, using the same application method.
- Application time is 6-8 hours.
- the patients may choose to apply at day time or night based on different functions.
- the application methods are basically the same as the application methods for OCULAXTM. Minor adjustments may be necessary for different diseases and acupoints, as can be appreciated by those skilled in the art.
- the following is an exemplary procedure intended to teach a patient about using the acupoint patches.
- the patient is to wash face and apply to Zanzhu, temple and Sibai, before bed time.
- the patient should apply skincare product before application of acupoint patches.
- the patient can remove the patches. The patient applies continuously for ten days, stop for 3-5 days and then continue.
- the acupoint patches are generally prepared as follows:
- polyester film Coat both side of polyester film (0.09.about.0.15 mm thick) with medical organic silicon anti-sticking materials. The coating should be even and of an appropriate thickness.
- An exemplary ratio of the main ingredients is: Ligusticum 19 mg, Salvia Root 17 mg, Tangkuei 11 mg, Chrysanthemum 33 mg.
- auxiliary ingredients are Polyacrylic adhesives and Azoo.
- Process of herb extraction Extract the valid composition from Ligusticum, Salvia Root, Tangkuei and Chrysanthemum. Concentrate and dry the extracts and make them into small powder for later use.
- the flowchart of the herb extraction process is shown in FIG. 5 . This process involves extracting water-soluble components from the herbal ingredients, filtering the water-soluble fraction (filtrate) from the solid herbal components, and drying the filtrate to produce a dried, water-soluble filtrate of each of the herbal materials.
- Polyester thin plastics First iron the definite-thickness polyester thin plastics by electricity. Second, evenly apply the organic-silicon paste-proofing agent on the polyester thin plastics. Stove the polyester thin plastics for later use.
- Process of the silk First, process a special waterproofing on weaved silk. Then plate Aluminum on the silk for later use.
- Process of the herbs mixture Weigh certain amount of polyacrylate emulsion. While agitating the polyacrylate, add quantify extracts of Ligusticum, Salvia Root, Tangkuei and Chrysanthemum one by one. 60 minutes later, add some trans-derma promoter, wetness retainer and fragrance. Then agitate for 30 minutes. Test the PH value of the solution till the PH value showing at the middle value. At last, filter the solution for later use.
- the release of herbal extracts is controlled by the transdermal promoter and measurements of nano-processed particles. It also controls the density of the blood medicine so that it can control the pace of the treatment.
Abstract
A method of applying dermal patches to acupoints in order to treat medical conditions. The dermal patches can contain extracts of herbal materials.
Description
- The present application is a divisional application which claims the benefit of priority from U.S. patent application Ser. No. 10/648,026, filed on Aug. 26, 2003 and titled ACUPOINT PATCH, which claims the benefit of priority from U.S. Provisional Patent Application No. 60/406,557, filed on Aug. 27, 2002 and titled ACUPOINT PATCH. Each of these applications is incorporated herein by reference in its entirety.
- The present invention relates to herbal medicine and more particularly relates to therapeutic patches which are applied to various locations of a patient for therapeutic purposes.
- For a long time, herbal medicine and herbal treatment in China have enjoyed seemingly mythical healing powers. As early as over three thousand years ago, BIAN Que and HUA Tuo, both prestigious doctors of Chinese medicine, have applied the fundamental principles of “stimulating blood circulation for relaxing muscles and joints” to stimulating acupoints on a patient's body for relaxing and easing purposes.
- As will be described in the present application, the essences of natural herbs are extracted to make therapeutic patches of the present invention, based on the principles of Chinese medicine and acupuncture. When applied to acupoints around the eyes, the patches of the present invention can achieve an effect similar to, and yet better than, that of acupuncture. The patches of the present invention can relax muscles, nerves and blood vessels around the eyes through painless and easy application. They also help alleviate eye fatigue and give the patient better vision.
- Acupoints
- Acupuncture, with a history dating all the way back to several thousand years in China, is now widely recognized in western medical field. During recent years, scientists have done researches as well as anatomic, histochemical, and algesia physiologic experiments based on contemporary medical knowledge while continuing the development of acupuncture. Phenomena and the nature of the main and collateral channels have been studied from different perspectives. Issues such as the connection between acupuncture points and feelings, as well as that of acupuncture points and body organs have been researched to promote the benefits of combining acupuncture and contemporary medical science. As such, acupuncture has been a focus of the international medical field. It is known to all that acupuncture cures diseases by stimulating specific locations, namely acupoints, of the body. Why is acupuncture applied to acupoints, instead of other parts of the body? A brief introduction is as follows.
- The nature of acupoint energy substance is a cytology and biochemistry issue. Recent research indicates that main and collateral acupoints are points consisting of cells containing a relatively large amount of adenosine triphosphate (ATP). Adenosine is the factory that generates power for the cells. It contains abundant ATP synthetic enzyme and is capable of producing a large amount of ATP energy. During experiments, tissue cells taken from such acupoints such as Zusanli, Hegu and Quchi, as well as from non-acupoint locations were dyed and observed under microscope. Comparison indicated that the adenosine inside these cells increased and showed no deformity. Therefore, we can draw the conclusion that an increasing amount of good quality adenosine can produce a large amount of ATP energy and enhance the functions of different organs and fluid mobility. When acupoints are stimulated with needles, or other objects such as medicated patches, this system will produce a large amount of good quality energy to provide for and to carry different necessary substances and nutrients.
- The Nobel Prize in Chemistry was awarded, in 1997, to two scholars for their elucidation of the enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP). One of the researchers who studied cell passage ions had verified the mechanism of acupuncture. In addition to a large amount of good quality adenosines, low cell electrical resistance and high current magnitude, channel and acupoint cells are also featured with good membrane permeability, more intercellular passages, good cell viability and complete ATP synthetic enzyme.
- Recent studies of channel and acupoint functions have provided additional inspirations. Research has indicated that the concentrations of calcium ions (Ca++) at channels and acupoints are higher than non-channel or acupoint locations. It has been found through experiments that stimulating a certain channel with needles resulted in increase of calcium ion concentrations at other acupoints on this channel. When any pathological change exists in a certain organ, the calcium concentrations at surrounding acupoints experienced abnormal changes, which proved that calcium ion was a key indicator of channel movements. In addition, Xiao-Song G U, et al., have recently found that electronic microscope observation of the differential protein of sensory nerve indicated that 29 KD protein was only found in the cyton and process of
level 1 sensory neurons. Stimulating acupoints resulted in the secretion of active substances and enhanced the bridging function of 29 KD protein. The amount of information passing through the channels increased, resulting in strong interactive stress and achieving internal balance. 29 KD protein transmits more than just biological electrical signals. It can also transmit a variety of ion substances or small molecule substance. This kind of transmission is completed through continuous transmission by 29 KD protein. This is the mechanism underlying the effect of stimulating channels and acupoints. - Disadvantages of Acupuncture
- Acupuncture has a history of over three thousand years in China. Over three thousand years ago, Chinese doctors started to cure different diseases with acupuncture. Recently, acupuncture has been widely used to treat eye diseases and ailments. The mechanism of alleviating and curing eye diseases involves regulating the channels and the vegetative nervous system. Then observation is on the artery peripheral plexus and the capillary artery front plexus formed by adrenalinergic nerves and cholinergic nerves around the small blood vessels distributed at certain acupoints with fluorescence organ chemical method. Experimental morphology proved that they were all fibers of sympathetic ganglions with the functions of controlling peripheral circulation resistance and local blood circulation. Using histological method, it was also observed that the cholesterase small nerve tracts consisting of the primitive marrow fiber inside the axiom nerve branches penetrated to deep underneath the acupoints, and extended to close to the capillary artery along to the small artery and vein before forming free ends. They then joined the capillary wall nerves and the vegetative nerves. Therefore, sympathetic nerves are considered an important part of the channels.
- Acupuncture cures eye diseases by stimulating acupoints around the eyes and adjusting functions of the vegetative nerves. Microcirculation is promoted, and so is oxygen and nutrients transmission around the eye acupoints. Microcirculation stasis is alleviated, and the ancillary muscles around the eyes are regulated and relaxed. This results in complete regulation and adjustment of the eyes. In the meantime, it also helps reduce tension of the cerebral cortex and thus achieves relaxation, as well as improving sleep and memory.
- Acupuncture has represented an essential part of traditional Chinese medicine. Its healing powers and effects have been widely recognized. We all know that in acupuncture, needles are used to stimulate acupoints for promoting blood circulation and relaxing nerves and muscles. Therefore, many ailments, discomforts or sicknesses can be cured with acupuncture therapy. Many people have become aware that acupuncture has an advantage in relieving pains and regulating immunity that is not matched by western medicines. However, acupuncture has its disadvantages too. First, although they are aware of the benefits of acupuncture, many people refuse to accept it as a therapy because of their phobia of pain, namely from the needles. Unable to overcome the fear of needles, they have no choice but to avoid acupuncture altogether. To these people, acupuncture is good, but it would only be perfect if it would not cause any pain. Second, recent reports have pointed out that acupuncture is only capable of relaxing local areas and the effects are temporary too. In acupuncture, the needles stay for 20-30 minutes. In about two hours after treatment is finished, the effect of acupuncture starts to diminish. One cannot work or sleep while carrying needles on the body. How to extend the effect of acupuncture has become a new research subject. As will be described in the following, the present invention by inventor Liqin SUN can replace needles. While reducing the pain resulted from treatment, it also expands the scope of treatment. It is essentially “acupuncture without needles.”
- A method of using acupoint patches, an apparatus and a method of making acupoint patches is disclosed. The acupoint patch of the present invention uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. It originates from acupuncture but easily surpasses acupuncture. As the essence of traditional Chinese medicine, acupuncture has been studied and developed during recent years to achieve better effects and minimum side effects. Acupoint patch application in accordance with the present invention now reaches beyond what acupuncture therapy can deliver.
- As will be described herein, the acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture. As previously mentioned, acupuncture can only relax ciliary muscles (effective on pseudomyopia) and only has a temporary effect. The reason is because in acupuncture, the needles only stay for 20-30 minutes. In about two hours after the treatment finishes, the effect of acupuncture starts to diminish. The successful experiment of the acupoint patch of the present invention has overcome the problem of the temporary effect of acupuncture therapy. It is also the first painless therapy. Patients only need to apply the acupoint patch of the present invention to designated acupoints on the face (Zanzhu, temple, Sibai) before bedtime to achieve the desired results.
- Also, application of the acupoint patch of the present invention is easy and safe. It is suitable for patients of different ages. In addition, the acupoint patch of the present invention not only has the transdermal absorption feature of traditional plasters, but also uses controlled release technologies so that the herbal nutrients enter blood circulation at an even speed, to ensure consistent blood medicine concentration and to avoid blood medicine concentration peak/trough problem.
-
FIG. 1 illustrates the blood medicine concentration (in ng/ml) vs. application time (in hour). -
FIG. 2 illustrates blood medicine concentration with peak and trough phenomenon. -
FIG. 3 shows steady blood medicine concentration over time, where the treatment zone is more stabilized. -
FIG. 4 illustrates a comparison of the acupoint patch of the present invention and other products in terms of blood medicine concentration vs. time. -
FIG. 5 illustrates an exemplary flow chart for the herbal extraction process in accordance with the present invention. - A method, apparatus and method of making medicated patches is disclosed. In the description that follows, numerous terminology in herbal medicine, acupuncture and acupoints will be referenced, using terms familiar to those skilled in the art. Also, the phrase “acupoint patch” and Applicant's trademark “OCULAX™” are used interchangeably in the present application, as they both refer to the transdermal acupoint patches for the controlled release of herbal extracts through the acupoints of a patient's body.
- Disadvantages of Traditional Plasters
- Transdermal medicine has been used in therapies as early as in the ancient times. Traditional Chinese plasters are some of the examples. Plasters help overcome the problems of pain and time limitation of acupuncture. However, the effect of plasters is less desirable than that of acupuncture, due to their limited permeability. In addition, although traditional plasters do have some of the characteristics of transdermal patches, the dosages are usually not precise. Precise control and maintenance of the desired blood medicine concentration are difficult to achieve, thus resulting in unbalanced blood medicine concentration (concentration peaks and lows). That is to say, during the first two hours after plasters are applied, the amount of medicine entering blood circulation is higher than the required amount, whereas after two hours, the amount of medicine entering blood circulation becomes insufficient.
- In our experiment, we applied 2% monarkite plasters of the same size to two patients. Their blood medicine concentrations differed by several times. This was due to inaccurate plaster thickness as well as different physiques of the patients.
FIG. 1 illustrates the blood medicine concentration (in ng/ml) vs. application time (in hour). - OCULAX™—Acupoint Patch of the Present Invention
- The acupoint patch of the present invention, commercially called OCULAX™, uses natural herbs as raw materials. It is made by combining traditional Chinese acupuncture therapy and contemporary transdermal controlled release technologies. It originates from acupuncture but easily surpasses acupuncture. As the essence of traditional Chinese medicine, acupuncture has been studied and developed during recent years to achieve better effects and minimum side effects. Acupoint patch application in accordance with the present invention now reaches beyond what acupuncture therapy can deliver.
- As will be described herein, the acupoint patch of the present invention is made with natural herb extracts using contemporary transdermal absorption technologies based on the characteristics of different acupoints. They can stay on the skin for 6-8 hours, during which period natural herb essence enters blood circulation and performs a sustainable regulating function. This is a feature unrivaled by traditional acupuncture. As previously mentioned, acupuncture can only relax ciliary muscles (effective on pseudomyopia) and only has a temporary effect. The reason is because in acupuncture, the needles only stay for 20-30 minutes. In about two hours after the treatment finishes, the effect of acupuncture starts to diminish. The successful experiment of the acupoint patch of the present invention has overcome the problem of the temporary effect of acupuncture therapy. It is also the first painless therapy. Patients only need to apply the acupoint patch of the present invention to designated acupoints on the face (Zanzhu, temple, Sibai) before bedtime to achieve the desired results.
- Also, application of the acupoint patch of the present invention is easy and safe. It is suitable for patients of different ages. In addition, the acupoint patch of the present invention not only has the transdermal absorption feature of traditional plasters, but also uses controlled release technologies so that the herbal nutrients enter blood circulation at an even speed, to ensure consistent blood medicine concentration and to avoid blood medicine concentration peak/trough problem.
- Acupoint Patches (OCULAX™) in More Detail
- There have been plenty of conventional healthcare products directed at preserving vision, relaxing eyes, improving sleeping patterns, and alleviating eye fatigue. Most of these conventional products are taken orally. The acupoint patch of the present invention is made of pure, natural herb extracts by combining traditional Chinese acupuncture and contemporary transdermal absorption controlled-release technologies. The acupoint patch in accordance with the present invention is a product with the following important implementation features:
- 1. Use of Advanced Technology:
- A. It combines acupoint therapy principles in traditional Chinese acupuncture;
- B. It uses the state-of-the-art transdermal absorption controlled release technologies available only in recent years;
- C. It is made of natural herb extracted with nano-technology;
- D. It is a multi-layer, e.g. five-layer patch.
- 2. Characteristics in Application of Acupoints:
- A. Patch application acupoints include Zanzhu, temple, Sibai, Fengchi, Jingming, Touwei, Yinxiang, Yingtang, Yifeng and Anmian;
- B. The acupoint patch is applied to the designated acupoints before bed time and taken off the following morning. The application time is 6-8 hours.
- C. The acupoint patch can be applied at any time without causing any pain.
- 3. Characteristics in Raw Materials Used:
- Raw materials include pure natural herbs such as Tangkuei (Angelica sinensis), Ligusticum (Ligusticum wallichii), chrysanthemum, and Salvia root (Salvia miltiorrhiza). These ingredients have no side effect of whatsoever. Tangkuei, Ligusticum, chrysanthemum and Salvia root can all promote blood circulation, regulate nervous system and reduce muscle spasm.
- 4. General Characteristics:
- A. Acupoint patch helps achieve all the benefits of painless acupoint therapy.
- B. Transdermal absorption controlled-release technology are used to avoid the blood medicine concentration peak/trough effect of traditional oral medicines.
- The unique characteristics of the acupoint patch of the present invention are attributable to the fact that it is the combination of traditional Chinese acupuncture and modern technologies. It follows both the principles of traditional Chinese acupuncture—applying natural herbs at acupoints—and combines modern transdermal absorption controlled-release technologies. As a result, Oculax can release effective ingredients at the acupoints consistently for a relatively longer period of time, and thus, regulate the nerves, muscles, and blood vessels around the eyes and in the head to promote eye and head blood circulation and to achieve the goal of relaxation. It helps in different types of eye problems, such as dry eyes, eye fatigue, vision deterioration, photaesthesia and tearing, myopia, presbyopia, glaucoma, and cataract. It also alleviates migraine, dizziness and insomnia. It is the textbook example of combining Chinese medicine with western medicine. OCULAX™ has surpassed conventional oral medicines or eye drops and opened up a new era for eye maintenance products.
- The acupoint patch of the present invention may be made of natural herbs such as Ligusticum, Tangkuei, Salvia root, and chrysanthemum. Records in pharmacopoeia, e.g. ZUENG Hu-Zhan et. al, MODERN STUDY OF TRADITIONAL CHINESE MEDICINE, Vol. 1-6, Xue Yuan Press, Beijing, China, 1999, ISBN 7-5077-1320-2, indicate that they have the following functions:
- Ligusticum—Promote blood and Qi circulation. Ligusticum can remarkably increase brain blood flow and improve mater microcirculation and flow. It has an evident effect in alleviating chronic microcirculation disturbance, especially bulbar conjunctiva microcirculation disturbance.
- Scholars have observed the effect of Ligusticum drops on the brain blood circulation speed of cerebral arteriosclerosis patients using a cranial Doppler ultrasound instrument. Twenty-one cerebral arteriosclerosis patients were given Ligusticum drops. The changes of their brain blood vessels and brain blood circulation speeds were observed using cranial Doppler ultrasound blood flow analyzer. The results indicated that Ligusticum drops could remarkably improve the vasomotion functions, lower blood viscosity, and promote brain blood circulation of cerebral arteriosclerosis patients. This indicates that Ligusticum is a good product for prevention of cerebral arteriosclerosis.
- Research has also been done using Ligusticum injection to treat bulbar conjunctiva microcirculation disturbance due to cerebral thrombus. Ten thrombus patients were given intravenous injection of 10 ml of 10% Ligusticum. Before injection, bulbar conjunctiva microcirculation was observed using a regular method. The results indicated that alleviation of bulbar conjunctiva microcirculation disturbance was evident after Ligusticum was injected, mainly reflected in improved flow, faster circulation, reduced cell concentration or free accumulation. These results were seen 20 minutes after Ligusticum was injected and was the most evident in 60 minutes after the injection. In addition, Ligusticum also has a remarkable effect of dilating blood vessels.
- Salvia Root—Promote blood and Qi circulation, remove blood stasis and alleviate pain, promote micro blood circulation. It has a remarkable effect in improving microcirculation, especially eye bulbar conjunctiva microcirculation.
- Experiments have proven the effect of Salvia root extract on treating microcirculation disturbance. Salvia root extract can remarkably dilate the capillaries of rabbits with microcirculation disturbance. In the experiment, rabbits that had been given intravenous injections of 10% macromolecule dextrose were given Salvia root extract. The effect of Salvia root extract on the capillaries and plasma lactic acid content was observed. The results indicated that intravenous injection of different dosages of Salvia root and Salvia root essence could both promote the blood circulation of rabbits with eye bulbar conjunctiva microcirculation disturbance and mesenterium microcirculation disturbance. It also helped in peripheral circulation and thus, alleviated metabolism problem caused by cell ischemic problem and anoxia.
- Research has also indicated that Salvia root has an anti-aging function. Scholars have compared the effects of Salvia root and vitamin E on the SOD and LPO of aged rats. The effects of Salvia root are better than those of vitamin E. The results indicated that Salvia root could evidently improve the activity of the erythrocuprein in the red cells, heart, liver and kidney of aged rats (P<0.01). Salvia root also remarkably lowered the content of peroxide fat in the serum, heart, liver and kidney of the same aged rats (P<0.01). Compared with vitamin E, Salvia root has better effects.
- Tangkuei—Promote blood and Qi circulation. Major results include improved flow, faster flow speed and improvement of fundus blood circulation. Experiments and research has indicated that Tangkuei is the ideal ingredient to regulate blood vessel functions. Tangkuei can dilate peripheral blood vessels, lower blood resistance, and improve blood circulation. Experiments have shown that Buerger's disease patients experienced improvement of blood circulation after one month of Tangkuei injection. The effective rate is 60%.
- Research has proven that the effective ingredient of Tangkuei is ferulic acid, which can dilate separated major arteries. Sedated animals were given intravenous injection of 50 mg/kg ferulic acid sodium. Arteria femoralis blood circulation was increased and external blood vessel resistance was reduced. Japanese scholars have proven through experiments that in addition to regulating blood pressure, Tangkuei can also lower eye pressure and reduce ventricular water production. Therefore, this effect is considered attributable to both peripheral and central factors.
- Other research has indicated that brewed Tangkuei soup can remarkably improve learning memory of white rats. The memory of rats was observed using passive avoidance conditioned reflex—diving platform experiment. The results indicated that memories of rats and repeated response abilities of rats were improved to different degrees.
- Chrysanthemum—Improve vision and refresh, eliminate wind and clear heat. It can be used to treat red eyes, swelling and pain, headache and insomnia, and blurred vision and dizziness. It can dilate blood vessels, increase blood flow and delay the aging process.
- Experiments have proven that chrysanthemum injection can dilate blood vessels and increase blood flow. Thoracic sedated cats were given intravenous injection of 1.5-2.0 g/kg of chrysanthemum. Coronary venous sinus flow was increased by 93% immediately. During the 40 minutes of continuous observation, the coronary flow was increased as compared to that before the injection. In separated rabbit heart perfusion application, the coronary flow was increased by 61% and 53% respectively in one minute and three minutes after application of medicine as compared to that before the application. Chrysanthemum injection can also remarkably dilate skin and organ blood vessels. Based on this, chrysanthemum is used in OCULAX™ to improve blood circulation and to increase oxygen and nutrients supplied to the eyes and the brain blood vessels.
- Research has proven the anti-aging function of chrysanthemum. Experiments were done to observe the effect of chrysanthemum immersion liquid on young silkworms. Results indicated that in addition to extending age, chrysanthemum immersion liquid could also increase length and weight of silkworms and promote their development. This proves that chrysanthemum has an anti-aging function.
- The above natural herbs have no side effects. When applied at night for 6-8 hours, the natural nutrients can enter blood circulation through the skin to relax nerves, blood vessels and muscles around the eyes and to alleviate eye fatigue. They can promote brain blood circulation, help in sleep and improve memory.
- While these natural herbs currently come from China and/or the United States, other sources may be available to those skilled in the art of extracting herbal essences based on the description herein. All these materials are pure natural herb extracts, and their specific information are provided in Tables 1-4 of the present application.
- Transdermal Controlled-Release Patch
- Technical characteristics of the acupoint patches are as follows: Due to excessive toxins or ineffective peak/trough medicine concentration of regulation medication methods (oral taking, injection, etc.), controlled release technologies have attracted more and more attention. During the past ten years, research on controlled medicine release has developed rapidly. A significant aspect of such research, transdermal treatment system, has experienced the most radical development and become a new star using the highest technologies. The acupoint patch of the present invention is a patch made of natural herbs using transdermal absorption method. It is directly applied to acupoints around the eyes and features characteristics not possessed by oral medicines or eye drops. Preferably, the acupoint patch of the present invention has five layers with different natures and functions, as will be described below:
- 1. LINING LAYER: Impermeable to medicines, provide protection and supporting functions.
- 2. STORAGE LAYER: Medicines are evenly distributed at this plastic layer.
- 3. CONTROLLED RELEASE LAYER: Serves to control and release medicines at the required speed.
- 4. PRESSURE SENSITIVE LAYER: Attaching the acupoint patch to the skin can provide an explosive dosage of medicine so that medicines can saturate the cuticle quickly and enter into body blood circulation.
- 5. PROTECTION AND NON-STICKING LAYER: Remove this layer, before applying the acupoint patch to the patient's acupoint(s).
- Quality Standards
- The following quality specifications may be adopted for ensuring the quality of acupoint patches of the present invention:
- 1. APPEARANCE: The acupoint patch is a round patch with one side coated with self-adhesive medicine film. Each patch is 2.27 square centimeters.
- 2. DIMENSIONS: Each set consists of six round patches attached to 4×7 centimeter non-sticking plastic protection film. Each patch is a dark brown patch. Even medicine layer of consistent color should be observed in any indoor location without direct sunlight. There should be no detachment of the medicine layer. The plastic side should be even, clean and free from areas not covered by medicines.
- 3. INGREDIENTS: The main ingredients of each set of patches include Ligusticum, Salvia root, Tangkuei and chrysanthemum. Other materials used include polyacrylic acid medical pressure-sensitive glue and polyester lining film.
- 4. FUNCTIONALITY: Relax nerves and muscles, refresh, alleviate fatigue, promote blood and Qi circulation, and distribute and minimize body heat.
- 5. SPECIFICATION:
- a. Weight variance: Take three sets of patches (total 18 pieces). Remove patches from the adhesive layer. Weigh each piece with 1/10000 balance and calculate the average weight. Compare the weight of each piece. The number of patches with a weight variance over +5% shall not exceed two. No weight variance exceeding +10% is allowed.
- b. Area of the patch: Take five patches. Measure the diameter of each round patch and calculate the area. The area of each set may not be less than 2.2 square centimeters (the sum of six patches.)
- c. Heat resistance and stability test: Place five patches in a freezer at −5.degree. and take out in 20 minutes. Touch with hand. The patches should feel sticky.
- d. Cold resistance and stability test: Place five patches in a freezer at −5.degree. and take out in 24 hours. Warm up to room temperature and touch with hand. The acupoint patches should feel sticky.
- Additional Advantages of Acupoint Patch of the Present Invention
- The acupoint patches of the present invention can achieve consistent application of medicines. Medicines released at a controlled speed enter body circulation consistently and steadily. This helps avoid peak/trough blood medicine concentrations of other medicine application methods and gives full play to the curative and regulating functions of the medicines. Since the medicines do not pass the digestive tract, destruction of the natural herb ingredients by pH, food and digestive fluids is avoided. Intestine or stomach upset, poor absorption and side effects of the metabolites due to stimulation of the digestive tract are also avoided. In addition to controlling medicine release, patients may also apply OCULAX™ based on their conditions.
-
FIG. 2 shows blood medicine concentration with peak and trough phenomenon.FIG. 3 shows steady blood medicine concentration over time, where the treatment zone is more stabilized. - The acupoint patch of the present invention brings out the curing effects of short biological half-life medicines that cannot be easily applied through oral taking or injection, as well as medicines with narrow “treatment window”, while limiting their side effects.
- Since the medicines do not pass the digestive tract, destruction of the natural herb ingredients by pH, food and digestive fluids is avoided. Intestine or stomach upset, poor absorption and side effects of the metabolites due to stimulation of the digestive tract are also avoided.
- The preliminary filtering function of the liver is bypassed to avoid dissolution of medicines by the liver and damage to the liver caused by medicines.
- The acupoint patch of the present invention is easy to use. It can be applied or removed based on the patient's need. It is painless and easily accepted by the patients.
- The acupoint patch can regulate eye nerves, blood vessels and muscles to restore normal eye operation.
- As can be appreciated, transdermal controlled medicine release helps achieve predetermined and longer medicine effective time, and improves medicine's effectiveness. Although the dosage is relatively small, OCULAX™ achieves satisfactory results without causing any side effects through transdermal absorption at acupoints. The frequency of medication and total dosage are reduced whereas the effectiveness is improved. This is the optimal eye care product.
- Application of the Acupoint Patch
- For treatment and care of the eyes, the patches of the present invention should be applied to three sets of acupoints around the eyes every night. The blood vessels, nerves and muscles passing these three sets of acupoints are introduced as follows:
- ZANZHU: This acupoint is located at the side above the eyebrows at the corner of the eye sockets. Distributed at this acupoint are frontal artery, vein and the medial lateral branches of facies frontalis.
- TEMPLE: This acupoint is located 0.5 centimeter from the tip of the brow. Distributed at this acupoint are the temporal branches of nervus facialis, and orbital arteries and veins.
- SIBAI: This acupoint is below the pupil at the inferior orbital socket. Distributed at this acupoint are branches of facial arteries and veins. Orbita arteries and veins are distributed around nervus facialis and inferior orbital nerves.
- The acupoint patch of the present invention thus helps in absorption of natural herbal nutrients by using acupoint patch mechanism. The acupoint patch of the present invention works via the nerve-incretion-immunity system as follows:
- Patch acupoints→Body→Participation by the nervous system, the immune system and the immune system→(feedback)→the body forms a new stable internal environment.
- The acupoint patch of the present invention uses natural herb extracts as raw materials. It is made based on the mechanism of acupuncture and contemporary transdermal controlled medicine release technologies. With the advantages of the acupoints and the transdermal controlled medicine release, OCULAX™ can release medicines into blood vessels, nerves and muscles around the eyes in a short time without the pain of acupuncture. It saves time and improves vision-regulating effectiveness. OCULAX™ is truly an acupuncture therapy without needles.
- OCULAX™ application instructions: Apply OCULAX™ to the six designated acupoints (two on Zanzhu, two on the temples and two on Sibai) every night before sleep. OCULAX™ stays for 6-8 hours. During these 6-8 hours, the natural herb nutrients enter blood circulation directly through the acupoints at an even speed. The result is much better than that of 30 minutes of traditional acupuncture. It also solves the problem of short needle-staying time.
- The scientific features of the acupoint patches of the present invention. Based on conventional concepts, people usually take some nutrients such as vitamin A or comprehensive vitamins to care for their eyes. Orally taken nutrients are dissolved in the livers and the kidneys. Most of the nutrients are discharged and only 10-20% is absorbed. Even less nutrients actually reach the eyes and the effects are seen slowly. Other people use eye drops as eye care. However, eye drops only have a temporary relaxing effect and are therefore, not able to solve the problems. Since eyes are nerve end organs, regulating acupoints around eyes is the optimal method to alleviate eye fatigue. From the anatomy point of view, applying medicines around the eyes brings about the best effects. OCULAX™ patches are applied to acupoints around the eyes. Medicines enter the blood circulation in the fastest manner to achieve the goal of regulating. In addition, it is believed in contemporary medical science that the biological effectiveness of acupoint patches is better than that of oral medicines because of the natural herb nutrients sensitivity and amplification effects of the acupoints. OCULAX™ can promote local and general blood circulation, enhance metabolism, and improve local nutrition, cell immune and fluid immune functions.
-
FIG. 4 illustrates a comparison of OCULAX™ and other products in terms of blood medicine concentration vs. time. Note that Curve A represents oral medication, Curve B represents acupuncture, and Curve C represents OCULAX™. From the above figure we can tell that compared with oral medicines and acupuncture, OCULAX™ has a longer and more stable regulating function. - The herbal nutrient content of 6 pieces of OCULAX™ is 60 mg, 40% of which enters blood circulation after released through the skin. This means that approximately 24 mgs work on the eyes. The effect can last 6-8 hours. Among the 60 mg nutrients of oral medicines, 25% is absorbed by the body and only 10-20%, e.g. 1.5-3 mg work on the eyes. The effects can last 2-3 hours. The effect of acupuncture is highly desirable in a short period of time. But the effects only last for this short period of time. The effective time is only 15-20% of that of OCULAX™.
- Additional Application of Acupoint Patches
- Acupoint patches using transdermal controlled medicine release present a novel method of treating other ailments and illness. In addition to caring for the eyes, such acupoint patches can also be used at other acupoints to treat other illness, provided that they are applied with the proper herbal extracts. A more detailed description is as follows:
- Selection of Acupoints:
- Acupoints that can regulate and relax eyes: Zanzhu, temple, Sibai, Jingming, Fengchi
- Acupoints that can regulate sleep patterns: Anmian, Fengchi, Yifeng, temple
- Acupoints that can regulate the lungs and the tracheas: Feiyu, Tiantu, Dingchuan, Shenyu
- Acupoints that can regulate liver metabolism: Qimen, Riyue, Zhangme, Zhongwan, Ganyu, Piyu
- Acupoints that can alleviate nasal allergy: Yingxiang, Feiyu, Yintang, Dazhui, Bitong
- Acupoints that can regulate blood pressure: Yintang, Renyin, Fengehi, Yifeng, Dazhui
- Acupoints that can regulate sexual functions: Qihai, Kaiyuan, Zhongji, Qugu, Qichong, Guilai
- Acupoints that can treat dementia: Touwei, temple, Fengchi, Yifeng, Yintang
- Acupoints Selection Method and Related Blood Vessel And Nerve Distribution
- Yinxiang: Located at the muffle at the same level as the medial point of the outer edge of ala nasi. Passing this acupoint include facial artery and vein branches, as well as branches of nervus facialis and orbital nerves. Regulating this acupoint can alleviate nasal congestion, anosmia, nose bleeding, running nose, facial itching and swelling.
- Renying: Next to Adam's apple, located at point A of the neck and the frontal lip of sternocleidomastoid. Passing this acupoint include thyroid gland veins and branches of internal and external carotid arteries. Distributed in the superficial layer are neck nervus cutaneus, nervus facialis, and deep sympathetic nerves. Passing the outer side include nervus hypoglossus and nervus vagus. Regulating this acupoint can alleviate sore throat, panting, and dizziness.
- Yintang: Located in the middle point between the two brows. Regulating this acupoint can alleviate headache, carebaria, forehead pain and insomnia.
- Fengchi: Located at the pit above sternocleidomastoid. Passing this acupoint include branches of occipital arteries and veins and branches of occipital nervelets. Regulating this acupoint can alleviate headache, insomnia, blurred vision and glaucoma.
- Yifeng: Behind the earlobe at the pit between the lower jaw and the processus mastoideus. Passing this acupoint include ear arteries and veins, and ear major nerves. At the deeper level is the nervus facialis node processus mastoideus. Regulating this acupoint can alleviate tinnitus, deafness and blurred vision.
- Anmian: Located at the middle point between Yifeng and Fengchi. Regulating this acupoint can alleviate insomnia, dizziness, headache and palpitation.
- Dazhui: Located below the processus mastoideus of vertebrae cervicales VII, at the same level as the shoulder. Passing this acupoint include branches of carotid arteries, the back branches of cervical nerve VIII, and the median part of the back branches of
thoracic nerve 1. Regulating this acupoint can alleviate headache, coughing and panting. - Dingchuan: Located next to Dazhui. Passing these acupoints are the same nerves and blood vessels as those passing Dazhui. Regulating this acupoint can cure asthma and alleviate coughing.
- Jingming: Located at the pit above eye corner. Passing this acupoint include inner canthus arteries and veins. At the deeper level are main branches of eye arteries and veins. Passing this acupoint also include upper and lower trochlea nerves. At the deeper level are oculomotor nerves and rock nerves. Regulating this acupoint alleviates tearing, nyctalopia, dizziness, myopia and eye pain.
- Qimen: Located below the nipple between ribs VI. Passing this acupoint include intercostal arteries and veins (VI), and intercostal nerves (VI). Regulating this acupoint can alleviate liver pain, abdominal distension, sour regurgitation.
- Riyue: Located one rib below Qimen and the nipple between ribs VII. Passing this acupoint include intercostal arteries and veins (VII), and intercostal nerves (VII). Regulating this acupoint can cure choleplania, liver diseases, rib pain and vomiting.
- Zhangmen: Located at the side of abdomen below the tip of floating rib XI. Passing this acupoint include end of intercostal arteries (X) and below it is intercostals nerves (X). Regulating this acupoint can alleviate liver pain, abdominal distention, vomiting, indigestion and diarrhea.
- Zhongwan: Located on the median of the abdomen, four inches above the navel. Passing this acupoint include arteria epigastrica and vena superior, and the front branches of intercostals nerves (VII). Regulating this acupoint can cure choleplania, liver pain, stomachache, abdominal distention, reduce peristaltic sound, and alleviate vomiting and insomnia.
- Feiyu: Located below the processus mastoideus of thoracic vertebra m, 1.5 inches next to Shenzhu (GV12). Passing acupoint include the inner back branches of intercostals arteries and veins. At the deeper level are outer branches. Regulating this acupoint can reduce coughing, panting, chest pain, night sweat, and hot flash.
- Ganyu: Located below the crest of thoracic vertebra IX, 1.5 inches next to Jinsuo (GV8). Passing this acupoint include the inner back branches of intercostals arteries and veins, the inner back branches of thoracic nerves IX and X. At the deeper level are the outer branches. Regulating this acupoint can cure choleplania, rib pain, dizziness and back pain.
- Piyu: Located below the crest of thoracic vertebra XI, 1.5 inches next to Jizhong. Passing this acupoint include the back branches of intercostal arteries and veins, thoracic nerves XI and XII, the inner back branches. At the deeper level are the outer branches. Regulating this acupoint can alleviate stomachache, choleplania, abdominal distention, vomiting and dropsy.
- Shenyu: Located below the crest of lumbar vertebra, 1.5 inches next to Mingmen. Passing this acupoint include the back branches of loin arteries and veins (II), and the outer back branches of loin nerves. At the deeper level are the outer branches. Regulating this acupoint can alleviate dizziness, asthma, dropsy and lower back pain.
- Tiantu: Located on the medial point above the sternum. Passing this acupoint include the branches of subcutaneous arteria carotis, thyroid arteries. At the deeper level are tracheas. Behind the manubrium are innominate arteries and aorta. Passing acupoint also include the front branches of supraclavian nerves. Regulating this acupoint can reduce asthma, coughing, sore and swelling throat, aphonia and dry throat.
- Yongquan: Located on the pelma at the pit when toes are flexed, near the cross point of the front ⅓ and the back ⅔ of the pelma. Passing this acupoint include deeper arcus plantaris and musculus nerves. Regulating this acupoint can alleviate headache, dizziness, sore throat, dry tongue, hypertension and constipation.
- Zhongji: Located on the median of the abdomen, four inches below the navel. Passing this acupoint include branches of superficial napes arteries and veins, the branches of arteria epigastrica and vena inferior, and branches of femoris hypogastric nerves. Regulating this acupoint can cure impotence, frequent micturiction, spermatorrhea, female sexual coldness, morbid leucorrhoea, and menstrual disorder.
- Kaiyuan: Located on the median of the abdomen, three inches below the navel. Blood vessels passing this acupoint are the same as those passing Zhong Ji. Passing acupoint include the front inner branches of intercostal nerves XII. Regulating this acupoint can cure spermatorrhea, enuresis, impotence, difficult urination, and menorrhalgia.
- Qugu: Located at the middle point of the upper edge of symphysis pubis. Passing this acupoint include branches of arteria epigastrica inferior, obturator arteries, and branches of femoris hypogastric nerves. Regulating this acupoint can cure spermatorrhea, impotence, enuresis, menorrhalgia, and menstrual disorder.
- Qihai: Located on the median of the abdomen, 1.5 inches below the navel. The blood vessels and nerves passing this acupoint are the same as those passing Shimen. Regulating this acupoint can cure impotence, hernia, spermatorrhea, diarrhea, amenorrhea and menstrual disorder.
- Guilai: Located at four inches below the navel and two inches next to Zhongji. Passing this acupoint include arteria epigastrica and vena inferior as well as femoris hypogastric nerves. Regulating this acupoint can alleviate abdominal pain, and cure impotence, hernia and menstrual disorder.
- Qichong: Located at five inches below the navel and two inches next to Qugu. Passing this acupoint include superficial branches of napes arteries and veins and at the outer side are arteria epigastrica and vena. Passing this acupoint are also iliac nerves. Regulating this acupoint can cure impotence, vulva swelling, menorrhalgia and menstrual disorder.
- Applying the Patches
- The manufacture methods of these patches are the same as that of OCULAX™. They are also made of natural herb extracts by combining acupuncture and transdermal controlled release technologies. Chinese herbs used include tussilago farfara, perillaseed, tendril-leaved fritillary bulb, fruit of Chinese magnoliavine, fructus ligustri lucidi, golden cypress, Centipeda minima, magnolia flower, radix angelicae formosanae, selfheal, radix achyranthis bidentatae and ramulus uncariae rhynchophyllae.
- The patches are to designated acupoints based on their different functions, using the same application method.
- Application time is 6-8 hours. The patients may choose to apply at day time or night based on different functions.
- The application methods are basically the same as the application methods for OCULAX™. Minor adjustments may be necessary for different diseases and acupoints, as can be appreciated by those skilled in the art.
- Using the Acupoint Patch
- The following is an exemplary procedure intended to teach a patient about using the acupoint patches. First, the patient is to wash face and apply to Zanzhu, temple and Sibai, before bed time. For dry skin, the patient should apply skincare product before application of acupoint patches. After getting up the following morning, the patient can remove the patches. The patient applies continuously for ten days, stop for 3-5 days and then continue.
- Manufacturing Process
- The acupoint patches are generally prepared as follows:
- 1. Preparation of Chinese herbs: Extract essence of Ligusticum, Salvia root, Tangkuei and chrysanthemum, dry, grind and screen.
- 2. Preparation of polyvinyl materials: Process medical flesh color PVC with special physical method. Make self-stick materials with PET.
- 3. Preparation of polyester film: Coat both side of polyester film (0.09.about.0.15 mm thick) with medical organic silicon anti-sticking materials. The coating should be even and of an appropriate thickness.
- 4. Preparation of patches: Pour extracts of Ligusticum, Salvia root, Tangkuei and chrysanthemum mixed at the prescribed ratio into medical pressure-sensitive polyacrylic acid latex. Mix even and place in a coating machine for coating. Use PVC film as the base material and polyester film as the lining material. Dry in an oven. Cut into patches with a diameter of 17 mm. Inspect and pack to make finished products.
- There are two types of controlled release technologies, the application of which depends on the specific use of those skilled in the art.
- 1. Mix nitrogen ketone with the prepared herbs and pressure-sensitive latex. Place in a coating machine for coating. This is called transdermal absorption controlled release technology.
- 2. Coat the PVC material with herbs and put a controlled release film in the medicine layer to slow down the release process. It should be noted that different controlled release methods can be achieved based on different applications.
- Exemplary Ingredients of Acupoint Patches
- 1. An exemplary ratio of the main ingredients is: Ligusticum 19 mg, Salvia Root 17 mg, Tangkuei 11 mg, Chrysanthemum 33 mg.
- 2. Other herbs can be added as the ingredients besides Ligusticum, Salvia Root, Tangkuei and Chrysanthemum. This depends on the different types of eye ailments or diseases. The auxiliary ingredients are Polyacrylic adhesives and Azoo.
- Exemplary Manufacturing Process of OCULAX™
- 1. Process of herb extraction: Extract the valid composition from Ligusticum, Salvia Root, Tangkuei and Chrysanthemum. Concentrate and dry the extracts and make them into small powder for later use. The flowchart of the herb extraction process is shown in
FIG. 5 . This process involves extracting water-soluble components from the herbal ingredients, filtering the water-soluble fraction (filtrate) from the solid herbal components, and drying the filtrate to produce a dried, water-soluble filtrate of each of the herbal materials. - 2. Process of Polyester thin plastics: First iron the definite-thickness polyester thin plastics by electricity. Second, evenly apply the organic-silicon paste-proofing agent on the polyester thin plastics. Stove the polyester thin plastics for later use.
- 3. Process of the silk: First, process a special waterproofing on weaved silk. Then plate Aluminum on the silk for later use.
- 4. Process of the herbs mixture: Weigh certain amount of polyacrylate emulsion. While agitating the polyacrylate, add quantify extracts of Ligusticum, Salvia Root, Tangkuei and Chrysanthemum one by one. 60 minutes later, add some trans-derma promoter, wetness retainer and fragrance. Then agitate for 30 minutes. Test the PH value of the solution till the PH value showing at the middle value. At last, filter the solution for later use.
- The Manufacturing Process of OCULAX:
- A. Herbs Control:
- Evenly apply the processed solution on the processed silk by scraping or transfer. Control the quantity of the colloidal substance on the processed silk to no lower than 120 g/square meter. Cover the processed polyester thin plastics and cut it into round standard of 17 mm diameter. After Quality Control inspection, pack it into finished products. The structure is as the follows:
- 1. Silk Lining
- 2. Herbs Storage Layer
- 3. Protection Layer
- According to this manufacturing process, the release of herbal extracts is controlled by the transdermal promoter and measurements of nano-processed particles. It also controls the density of the blood medicine so that it can control the pace of the treatment.
- B. Controlled Releasing:
- First dissolve the herb extracts. Add by evenly applying the processed solution on the processed silk by scraping or transfer. Paste the release control film on the herbs storage layer and evenly apply the sensitivity reduction layer on the release control film layer. Cut it into appropriate standard pieces and cover the processed protection layer. Pack it into completed products. The structure is as the follows:
- 1. Silk Lining
- 2. Herb Storage Layer
- 3. Release Control Layer
- 4. Sensitivity Reduction Layer
- 5. Protection Layer
- The following tables include further information regarding ingredients used to make OCULAX™ patches.
TABLE 1 Product: Ligusticum Appearance: Brown Dosage Form: Powder Determination Result Specifications Solvent Total Ash 3.95% <10.00% Content: Acid-Insoluble 1.86% <2.0% 10% HCL Ashes: Loss on 3.96% <12.00% Drying: H20 Extract: 52.62% >27.00% H20 Dil. Eton 35.17% >26.00% 50% Eton Extract: Heavy Metal: Ok Not more than 1000/g E. coli: Negative Salmonella: Negative Bacter Total: Ok Not more than 1000/g Identification: Positive Purity: Positive
TLC Test: Ligusticum Wallichii Posibive
-
TABLE 2 Product: Salvia Root Appearance: Brown Dosage Form: Powder Determination Result Specifications Solvent Total Ash 3.28% <8.00% Content: Acid-Insoluble 1.71% <4.00% 10% HCL Ashes: Loss on 4.41% <7.00% Drying: H20 Extract: 44.06% >44.00% H20 Dil. EtOH 36.82% >38.00% 50% EtOH Extract: Heavy Metal: Ok Not more than 100 ppm E. coli: Negative Salmonella: Negative Bacter Total: Ok Not more than 1000/g Identification: Positive Purity: Positive
TLC Test: Salvia miltiorrhiza Positive
-
TABLE 3 Product: Tangkuei Appearance: Brown Dosage Form: Powder Determination Result Specifications Solvent Total Ash 4.05% <0.00% Content: Acid-Insoluble 2.01% <2.00% 10% HCL Ashes: Loss on 0.87% <7.00% Drying: H20 Extract: 47.89% >45.00% H20 Dil. EtOH 40.72% >40.00% 50% EtOH Extract: Heavy Metal: Ok Not more than 100 ppm E. coli: Negative Salmonella: Negative Bacter Total: Ok Not more than 1000/g Identification: Positive Purity: Positive
TLC Test: Angelica sinensis Positive
-
TABLE 4 Product: Chrysanthemum Appearance: Brown Dosage Form: Powder Determination Result Specifications Solvent Total Ash 3.66% <12.00% Content: Acid-Insoluble 2.80% <3.00% 10% HCL Ashes: Loss on 4.93% <10.00% Drying: H20 Extract: 55.30% >24.00% H20 Dil. EtOH 38.97% >25.00% 50% EtOH Extract: Heavy Metal: Ok Not more than 100 ppm E. coli: Negative Salmonella: Negative Bacter Total: Ok Not more than 1000/g Identification: Positive Purity: Positive
TLC Test: Chrysanthemum Norifolium Positive
- Although only a few exemplary embodiments of this invention have been described in detail above, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. Accordingly, all such modifications are intended to be included within the scope of this invention as defined in the following claims.
Claims (35)
1. A method of treating an eye of a patient, comprising:
(a) providing a dermal patch comprising one or more medicaments which promote blood circulation, relax muscles, or regulate nerve function; and
(b) applying the dermal patch to an acupoint of the eye of the patient, wherein the acupoint is selected from the group consisting of Sibai, temple, and Zanzhu.
2. The method of claim 1 , wherein step (a) further comprises providing a plurality of dermal patches, and wherein step (b) further comprises applying a dermal patch to each of the Sibai acupoint, the temple acupoint, and the Zanzhu acupoint of the eye of the patient.
3. The method of claim 2 , wherein step (b) comprises applying a dermal patch to each of the Sibai acupoint, the temple acupoint, and the Zanzhu acupoint of both eyes of the patient.
4. The method of claim 1 , wherein the one or more medicaments promotes blood circulation, relaxes muscles, and regulates nerve function.
5. The method of claim 1 , wherein the medicament comprises a dried, water-soluble filtrate of an herbal material selected from the group consisting of Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, chrysanthemum, tussilago farfara, perillaseed, tendril-leaved fritillary bulb, fruit of Chinese magnoliavine, fructus ligustri lucidi, golden cypress, Centipeda minima, magnolia flower, radix angelicae formosanae, selfheal, radix achyranthis bidentatae and ramulus uncariae rhynchophyllae.
6. The method of claim 1 , wherein the medicament comprises a dried, water-soluble filtrate of Ligusticum wallichii; a dried, water-soluble filtrate of Salvia miltiorrhiza; a dried, water-soluble filtrate of Angelica sinensis; and a dried, water-soluble filtrate of chrysanthemum,
7. The method of claim 1 , wherein the dermal patch is applied to the patient for a period of time of between 6 hours and 8 hours.
8. The method of claim 1 , wherein the dermal patch comprises a self-stick material and is adhered to the acupoint of the patient.
9. A method of treating a medical condition of a patient, comprising:
providing a dermal patch comprising one or more medicaments which promote blood circulation, relax muscles, or regulate nerve function; and
applying the dermal patch to an acupoint of the patient in order to treat the medical condition.
10. The method of claim 9 , wherein the medicament is a dried, water-soluble filtrate of an herbal material selected from the group consisting of Ligusticum wallichii, Salvia miltiorrhiza, Angelica sinensis, chrysanthemum, tussilago farfara, perillaseed, tendril-leaved fritillary bulb, fruit of Chinese magnoliavine, fructus ligustri lucidi, golden cypress, Centipeda minima, magnolia flower, radix angelicae formosanae, selfheal, radix achyranthis bidentatae and ramulus uncariae rhynchophyllae.
11. The method of claim 9 , wherein the acupoint is Yintang and the medical condition is selected from the group consisting of headache, carebaria, forehead pain and insomnia.
12. The method of claim 9 , wherein the acupoint is Fengchi and the medical condition is selected from the group consisting of headache, insomnia, blurred vision and glaucoma.
13. The method of claim 9 , wherein the acupoint is Yifeng and the medical condition is selected from the group consisting of tinnitus, deafness and blurred vision.
14. The method of claim 9 , wherein the acupoint is Anmian and the medical condition is selected from the group consisting of insomnia, dizziness, headache and palpitation.
15. The method of claim 9 , wherein the acupoint is Dazhui and the medical condition is selected from the group consisting of headache, coughing and panting.
16. The method of claim 9 , wherein the acupoint is Dingchuan and the medical condition is selected from the group consisting of coughing.
17. The method of claim 9 , wherein the acupoint is Jingming and the medical condition is selected from the group consisting of tearing, nyctalopia, dizziness, myopia and eye pain.
18. The method of claim 9 , wherein the acupoint is Qimen and the medical condition is selected from the group consisting of liver pain, abdominal distension, sour regurgitation.
19. The method of claim 9 , wherein the acupoint is Riyue and the medical condition is selected from the group consisting of choleplania, liver diseases, rib pain and vomiting.
20. The method of claim 9 , wherein the acupoint is Zhangmen and the medical condition is selected from the group consisting of liver pain, abdominal distention, vomiting, indigestion and diarrhea.
21. The method of claim 9 , wherein the acupoint is Zhongwan and the medical condition is selected from the group consisting of choleplania, liver pain, stomachache, abdominal distention, reduced peristalsis, vomiting and insomnia.
22. The method of claim 9 , wherein the acupoint is Feiyu and the medical condition is selected from the group consisting of coughing, panting, chest pain, night sweats, and hot flashes.
23. The method of claim 9 , wherein the acupoint is Ganyu and the medical condition is selected from the group consisting of choleplania, rib pain, dizziness and back pain.
24. The method of claim 9 , wherein the acupoint is Piyu and the medical condition is selected from the group consisting of stomachache, choleplania, abdominal distention, vomiting and dropsy.
25. The method of claim 9 , wherein the acupoint is Shenyu and the medical condition is selected from the group consisting of dizziness, asthma, dropsy and lower back pain.
26. The method of claim 9 , wherein the acupoint is Tiantu and the medical condition is selected from the group consisting of asthma, coughing, sore and swelling throat, aphonia and dry throat.
27. The method of claim 9 , wherein the acupoint is Yongquan and the medical condition is selected from the group consisting of headache, dizziness, sore throat, dry tongue, hypertension and constipation.
28. The method of claim 9 , wherein the acupoint is Zhongji and the medical condition is selected from the group consisting of impotence, frequent micturiction, spermatorrhea, female sexual coldness, morbid leucorrhoea, and a menstrual disorder.
29. The method of claim 9 , wherein the acupoint is Kaiyuan and the medical condition is selected from the group consisting of spermatorrhea, enuresis, impotence, dysuria, and menorrhalgia.
30. The method of claim 9 , wherein the acupoint is Qugu and the medical condition is selected from the group consisting of spermatorrhea, impotence, enuresis, menorrhalgia, and a menstrual disorder.
31. The method of claim 9 , wherein the acupoint is Qihai and the medical condition is selected from the group consisting of impotence, hernia, spermatorrhea, diarrhea, amenorrhea and a menstrual disorder.
32. The method of claim 9 , wherein the acupoint is Guilai and the medical condition is selected from the group consisting of abdominal pain, impotence, hernia and a menstrual disorder.
33. The method of claim 9 , wherein the acupoint is Qichong and the medical condition is selected from the group consisting of impotence, vulva swelling, menorrhalgia and a menstrual disorder.
34. The method of claim 9 , wherein the acupoint is Yinxiang and the medical condition is selected from the group consisting of nasal congestion, anosmia, nose bleeding, running nose, facial itching and swelling.
35. The method of claim 9 , wherein the acupoint is Renying and the medical condition is selected from the group consisting of sore throat, panting, and dizziness.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/831,588 US20080021421A1 (en) | 2002-08-27 | 2007-07-31 | Acupoint patch |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40655702P | 2002-08-27 | 2002-08-27 | |
US10/648,026 US7645462B2 (en) | 2002-08-27 | 2003-08-26 | Acupoint patch |
US11/831,588 US20080021421A1 (en) | 2002-08-27 | 2007-07-31 | Acupoint patch |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/648,026 Division US7645462B2 (en) | 2002-08-27 | 2003-08-26 | Acupoint patch |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080021421A1 true US20080021421A1 (en) | 2008-01-24 |
Family
ID=34272305
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/648,026 Expired - Fee Related US7645462B2 (en) | 2002-08-27 | 2003-08-26 | Acupoint patch |
US11/831,588 Abandoned US20080021421A1 (en) | 2002-08-27 | 2007-07-31 | Acupoint patch |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/648,026 Expired - Fee Related US7645462B2 (en) | 2002-08-27 | 2003-08-26 | Acupoint patch |
Country Status (2)
Country | Link |
---|---|
US (2) | US7645462B2 (en) |
CN (1) | CN1214785C (en) |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100255069A1 (en) * | 2004-09-24 | 2010-10-07 | Sunny Biodiscovery, Inc. | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of angelica sinensis, and methods of preparation thereof |
CN101890079A (en) * | 2010-04-29 | 2010-11-24 | 贵阳春科药业技术研发有限公司 | Medical preparation for preventing and treating rhinitis and preparation method thereof |
US8388794B2 (en) | 2008-07-16 | 2013-03-05 | Nitto Denko Corporation | Process for producing adhesive patch |
CN103127243A (en) * | 2011-11-22 | 2013-06-05 | 吉林省第二荣复军人医院 | Medicament for treating transaminase-increasing diseases caused by acute or chronic hepatitis and hepatic diseases |
US20170366965A1 (en) * | 2016-06-21 | 2017-12-21 | Chiun Mai Communication Systems, Inc. | Communication device, communication system and method therefor |
CN107875370A (en) * | 2017-12-19 | 2018-04-06 | 深圳健安医药有限公司 | For promoting enterocinesia exhaust to prevent the Chinese medicine composition and preparation method of intestinal adhesion |
CN109342636A (en) * | 2018-12-03 | 2019-02-15 | 国药集团新疆制药有限公司 | A kind of FUFANG XUELIAN JIAONANG identification method |
US11128715B1 (en) | 2019-12-30 | 2021-09-21 | Snap Inc. | Physical friend proximity in chat |
US11189299B1 (en) | 2017-02-20 | 2021-11-30 | Snap Inc. | Augmented reality speech balloon system |
US11190679B2 (en) | 2014-11-12 | 2021-11-30 | Snap Inc. | Accessing media at a geographic location |
US11195018B1 (en) | 2017-04-20 | 2021-12-07 | Snap Inc. | Augmented reality typography personalization system |
US11199957B1 (en) | 2018-11-30 | 2021-12-14 | Snap Inc. | Generating customized avatars based on location information |
US11206615B2 (en) | 2019-05-30 | 2021-12-21 | Snap Inc. | Wearable device location systems |
US11218838B2 (en) | 2019-10-31 | 2022-01-04 | Snap Inc. | Focused map-based context information surfacing |
US11228551B1 (en) | 2020-02-12 | 2022-01-18 | Snap Inc. | Multiple gateway message exchange |
US11249614B2 (en) | 2019-03-28 | 2022-02-15 | Snap Inc. | Generating personalized map interface with enhanced icons |
US11250075B1 (en) | 2017-02-17 | 2022-02-15 | Snap Inc. | Searching social media content |
US11250887B2 (en) | 2014-12-19 | 2022-02-15 | Snap Inc. | Routing messages by message parameter |
US11258749B2 (en) | 2017-03-09 | 2022-02-22 | Snap Inc. | Restricted group content collection |
US11265273B1 (en) | 2017-12-01 | 2022-03-01 | Snap, Inc. | Dynamic media overlay with smart widget |
US11281701B2 (en) | 2014-09-18 | 2022-03-22 | Snap Inc. | Geolocation-based pictographs |
US11290851B2 (en) | 2020-06-15 | 2022-03-29 | Snap Inc. | Location sharing using offline and online objects |
US11297399B1 (en) | 2017-03-27 | 2022-04-05 | Snap Inc. | Generating a stitched data stream |
US11294936B1 (en) | 2019-01-30 | 2022-04-05 | Snap Inc. | Adaptive spatial density based clustering |
US11297463B2 (en) | 2018-04-18 | 2022-04-05 | Snap Inc. | Visitation tracking system |
US11301960B2 (en) | 2015-01-09 | 2022-04-12 | Snap Inc. | Object recognition based image filters |
US11315331B2 (en) | 2015-10-30 | 2022-04-26 | Snap Inc. | Image based tracking in augmented reality systems |
US11314776B2 (en) | 2020-06-15 | 2022-04-26 | Snap Inc. | Location sharing using friend list versions |
US11317240B2 (en) | 2014-06-13 | 2022-04-26 | Snap Inc. | Geo-location based event gallery |
US11335067B2 (en) | 2017-09-15 | 2022-05-17 | Snap Inc. | Augmented reality system |
US11343323B2 (en) | 2019-12-31 | 2022-05-24 | Snap Inc. | Augmented reality objects registry |
US11349796B2 (en) | 2017-03-27 | 2022-05-31 | Snap Inc. | Generating a stitched data stream |
US11372608B2 (en) | 2014-12-19 | 2022-06-28 | Snap Inc. | Gallery of messages from individuals with a shared interest |
US11380051B2 (en) | 2015-11-30 | 2022-07-05 | Snap Inc. | Image and point cloud based tracking and in augmented reality systems |
US11388226B1 (en) | 2015-01-13 | 2022-07-12 | Snap Inc. | Guided personal identity based actions |
US11385763B2 (en) | 2017-04-27 | 2022-07-12 | Snap Inc. | Map-based graphical user interface indicating geospatial activity metrics |
US11392633B2 (en) | 2015-05-05 | 2022-07-19 | Snap Inc. | Systems and methods for automated local story generation and curation |
US11397517B2 (en) | 2016-12-09 | 2022-07-26 | Snap Inc. | Customized media overlays |
US11418906B2 (en) | 2017-04-27 | 2022-08-16 | Snap Inc. | Selective location-based identity communication |
US11429618B2 (en) | 2019-12-30 | 2022-08-30 | Snap Inc. | Surfacing augmented reality objects |
US11450050B2 (en) | 2018-08-31 | 2022-09-20 | Snap Inc. | Augmented reality anthropomorphization system |
US11451856B2 (en) | 2011-07-12 | 2022-09-20 | Snap Inc. | Providing visual content editing functions |
US11487794B2 (en) | 2018-01-03 | 2022-11-01 | Snap Inc. | Tag distribution visualization system |
US11491393B2 (en) | 2018-03-14 | 2022-11-08 | Snap Inc. | Generating collectible items based on location information |
US11496544B2 (en) | 2015-05-05 | 2022-11-08 | Snap Inc. | Story and sub-story navigation |
US11500525B2 (en) | 2019-02-25 | 2022-11-15 | Snap Inc. | Custom media overlay system |
US11503432B2 (en) | 2020-06-15 | 2022-11-15 | Snap Inc. | Scalable real-time location sharing framework |
US11507614B1 (en) | 2018-02-13 | 2022-11-22 | Snap Inc. | Icon based tagging |
US11523159B2 (en) | 2018-02-28 | 2022-12-06 | Snap Inc. | Generating media content items based on location information |
US11558709B2 (en) | 2018-11-30 | 2023-01-17 | Snap Inc. | Position service to determine relative position to map features |
US11574431B2 (en) | 2019-02-26 | 2023-02-07 | Snap Inc. | Avatar based on weather |
US11595569B2 (en) | 2014-07-07 | 2023-02-28 | Snap Inc. | Supplying content aware photo filters |
US11599241B2 (en) | 2015-11-30 | 2023-03-07 | Snap Inc. | Network resource location linking and visual content sharing |
US11601888B2 (en) | 2021-03-29 | 2023-03-07 | Snap Inc. | Determining location using multi-source geolocation data |
US11606755B2 (en) | 2019-05-30 | 2023-03-14 | Snap Inc. | Wearable device location systems architecture |
US11611846B2 (en) | 2016-02-26 | 2023-03-21 | Snap Inc. | Generation, curation, and presentation of media collections |
US11616745B2 (en) | 2017-01-09 | 2023-03-28 | Snap Inc. | Contextual generation and selection of customized media content |
US11617056B2 (en) | 2017-10-09 | 2023-03-28 | Snap Inc. | Context sensitive presentation of content |
US11625755B1 (en) | 2014-09-16 | 2023-04-11 | Foursquare Labs, Inc. | Determining targeting information based on a predictive targeting model |
US11625443B2 (en) | 2014-06-05 | 2023-04-11 | Snap Inc. | Web document enhancement |
US11631276B2 (en) | 2016-03-31 | 2023-04-18 | Snap Inc. | Automated avatar generation |
US11662576B2 (en) | 2015-03-23 | 2023-05-30 | Snap Inc. | Reducing boot time and power consumption in displaying data content |
US11670057B2 (en) | 2017-03-06 | 2023-06-06 | Snap Inc. | Virtual vision system |
US11670026B2 (en) | 2018-07-24 | 2023-06-06 | Snap Inc. | Conditional modification of augmented reality object |
US11675831B2 (en) | 2017-05-31 | 2023-06-13 | Snap Inc. | Geolocation based playlists |
US11704005B2 (en) | 2018-09-28 | 2023-07-18 | Snap Inc. | Collaborative achievement interface |
US11714535B2 (en) | 2019-07-11 | 2023-08-01 | Snap Inc. | Edge gesture interface with smart interactions |
US11722837B2 (en) | 2018-03-06 | 2023-08-08 | Snap Inc. | Geo-fence selection system |
US11734712B2 (en) | 2012-02-24 | 2023-08-22 | Foursquare Labs, Inc. | Attributing in-store visits to media consumption based on data collected from user devices |
US11750767B2 (en) | 2016-11-07 | 2023-09-05 | Snap Inc. | Selective identification and order of image modifiers |
US11751015B2 (en) | 2019-01-16 | 2023-09-05 | Snap Inc. | Location-based context information sharing in a messaging system |
US11765117B2 (en) | 2020-03-05 | 2023-09-19 | Snap Inc. | Storing data based on device location |
US11776256B2 (en) | 2020-03-27 | 2023-10-03 | Snap Inc. | Shared augmented reality system |
US11843456B2 (en) | 2016-10-24 | 2023-12-12 | Snap Inc. | Generating and displaying customized avatars in media overlays |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040265395A1 (en) * | 2003-06-30 | 2004-12-30 | Ying Sun | Device for delivery of reducing agents to barrier membranes |
US7476222B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of reducing the appearance of pigmentation with galvanic generated electricity |
US8734421B2 (en) * | 2003-06-30 | 2014-05-27 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating pores on the skin with electricity |
US7477938B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Cosumer Companies, Inc. | Device for delivery of active agents to barrier membranes |
US7479133B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating acne and rosacea with galvanic generated electricity |
US7477939B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of treating a wound with galvanic generated electricity |
US7507228B2 (en) * | 2003-06-30 | 2009-03-24 | Johnson & Johnson Consumer Companies, Inc. | Device containing a light emitting diode for treatment of barrier membranes |
US7486989B2 (en) * | 2003-06-30 | 2009-02-03 | Johnson & Johnson Consumer Companies, Inc. | Device for delivery of oxidizing agents to barrier membranes |
US7477941B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of exfoliating the skin with electricity |
US7477940B2 (en) * | 2003-06-30 | 2009-01-13 | J&J Consumer Companies, Inc. | Methods of administering an active agent to a human barrier membrane with galvanic generated electricity |
US7480530B2 (en) * | 2003-06-30 | 2009-01-20 | Johnson & Johnson Consumer Companies, Inc. | Device for treatment of barrier membranes |
GB2414675B (en) * | 2004-06-05 | 2006-09-06 | Dewan Fazlul Hoque Chowdhury | Transdermal drug delivery device |
GB2435426A (en) * | 2006-02-23 | 2007-08-29 | David William Richardson | Wound healing system and dressing containing a dried form of a liquid |
EP1839705A1 (en) | 2006-03-27 | 2007-10-03 | Universidad de Alcala | Transcutaneous laser therapy patch |
CA2701009C (en) * | 2007-09-28 | 2017-03-21 | Johnson & Johnson Consumer Companies, Inc. | Electricity-generating particulates and the use thereof |
US20090291127A1 (en) * | 2008-05-21 | 2009-11-26 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
US20100082088A1 (en) * | 2008-08-27 | 2010-04-01 | Ali Fassih | Treatment of sweating and hyperhydrosis |
US8150525B2 (en) * | 2008-08-27 | 2012-04-03 | Johnson & Johnson Consumer Companies, Inc. | Treatment of hyperhydrosis |
AU2009300184A1 (en) * | 2008-09-30 | 2010-04-08 | Teikoku Pharma Usa, Inc. | Transdermal extended-delivery donepezil compositions and methods for using the same |
CN101766695B (en) * | 2009-01-06 | 2012-07-04 | 天津奥克莱斯生物技术有限公司 | Point eye mask and preparation method and application thereof |
GB2467377A (en) * | 2009-02-02 | 2010-08-04 | Nemaura Pharma Ltd | Transdermal patch with extensor means actuated to expel drug towards the skin of a patient |
US20120089232A1 (en) | 2009-03-27 | 2012-04-12 | Jennifer Hagyoung Kang Choi | Medical devices with galvanic particulates |
KR20120091335A (en) | 2009-11-13 | 2012-08-17 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Galvanic skin treatment device |
US20100178307A1 (en) * | 2010-01-13 | 2010-07-15 | Jianye Wen | Transdermal anti-dementia active agent formulations and methods for using the same |
KR20110091461A (en) * | 2010-02-05 | 2011-08-11 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Lip compositions comprising galvanic particulates |
CN102781406B (en) * | 2010-03-01 | 2015-07-08 | 强生消费者公司 | Skin care composition having desirable bulk color |
US20110236491A1 (en) * | 2010-03-25 | 2011-09-29 | Jeannette Chantalat | Topical anti-inflammatory composition |
US20130171200A1 (en) * | 2011-12-30 | 2013-07-04 | Tuming You | Heat Patch for Diabetes |
CN104644747A (en) * | 2013-11-15 | 2015-05-27 | 王文革 | Eye compress liquid mainly for treating pseudomyopia |
CN106163463A (en) * | 2014-01-22 | 2016-11-23 | 马尔西奥·马克·阿布雷乌 | It is configured to the device processed in ABREU brain fever passage offer |
CN104146875B (en) * | 2014-08-06 | 2017-06-23 | 珠海横琴早晨科技有限公司 | A kind of multi-functional spontaneous regulation temperature three dimensional face mask |
CN105411755A (en) * | 2015-11-17 | 2016-03-23 | 桐乡市施康制药厂有限公司 | Manufacturing process of medical adhesive tape |
CN106063743A (en) * | 2016-05-24 | 2016-11-02 | 深圳市本恩生物科技有限公司 | Chinese herbal medicine non-woven fabrics and preparation method thereof |
CN106728937A (en) * | 2016-12-16 | 2017-05-31 | 潘永锋 | A kind of Chinese medicine for treating eye illness |
CN108371632A (en) * | 2018-03-22 | 2018-08-07 | 曹洪乾 | Make tranquil dizzy cream |
CN109528931A (en) * | 2018-11-28 | 2019-03-29 | 菲皇(广州)生物科技有限公司 | A kind of eye cold compress patch includes composition formula and cold compress patch preparation method, application |
CN109700889A (en) * | 2019-03-05 | 2019-05-03 | 朱月新 | A kind of Chinese medicine composition and preparation method thereof of health care eyes |
CN109966340A (en) * | 2019-05-14 | 2019-07-05 | 河北安耐哲新能源技术有限公司 | A kind of external medicine composition and its preparation method and application for eye |
CN110946847A (en) * | 2019-11-04 | 2020-04-03 | 上海交通大学医学院附属瑞金医院卢湾分院 | Local external application medicine pad pasting |
CN111616953A (en) * | 2020-06-24 | 2020-09-04 | 福建三和济医疗器械有限公司 | Therapeutic plaster for acupoint application |
CN112121103B (en) * | 2020-09-28 | 2021-10-22 | 杭州市余杭区第五人民医院 | Traditional Chinese medicine fumigation patch for preventing and controlling myopia of students and preparation method thereof |
CN112263389A (en) * | 2020-11-17 | 2021-01-26 | 中山大学中山眼科中心 | Ophthalmic medicine moxibustion plaster |
CN112717062B (en) * | 2021-03-04 | 2021-12-07 | 上海中医药大学附属龙华医院 | Traditional Chinese medicine composition for treating diabetic retinopathy |
CN115089633B (en) * | 2022-07-04 | 2023-10-24 | 兰守夕 | Composition for preventing and treating myopia, eye mask and preparation method |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4858604A (en) * | 1981-12-09 | 1989-08-22 | Nippon Zoki Pharmaceutical Co., Ltd. | Adhesive bandage |
US5162037A (en) * | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US20020151584A1 (en) * | 2000-09-26 | 2002-10-17 | Johns Hopkins University | Antiviral compositions and methods of use |
US20030082214A1 (en) * | 2001-08-17 | 2003-05-01 | Williams Robert O. | Topical compositions and methods for treating pain |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE53703B1 (en) * | 1982-12-13 | 1989-01-18 | Elan Corp Plc | Drug delivery device |
CN1113149A (en) * | 1994-06-23 | 1995-12-13 | 田树银 | Anti-inflammation medicine and its making method |
US5736154A (en) * | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
WO1999026571A1 (en) * | 1997-11-25 | 1999-06-03 | Theratech, Inc. | Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties |
JP2000044481A (en) * | 1998-07-30 | 2000-02-15 | Sunstar Inc | Preparation for external use for skin |
KR100452972B1 (en) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | Hydrogel composition for transdermal drug |
-
2003
- 2003-08-26 CN CNB031564178A patent/CN1214785C/en not_active Expired - Lifetime
- 2003-08-26 US US10/648,026 patent/US7645462B2/en not_active Expired - Fee Related
-
2007
- 2007-07-31 US US11/831,588 patent/US20080021421A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4858604A (en) * | 1981-12-09 | 1989-08-22 | Nippon Zoki Pharmaceutical Co., Ltd. | Adhesive bandage |
US5162037A (en) * | 1988-04-01 | 1992-11-10 | Whitson Laboratories, Inc. | Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration |
US20020151584A1 (en) * | 2000-09-26 | 2002-10-17 | Johns Hopkins University | Antiviral compositions and methods of use |
US20030082214A1 (en) * | 2001-08-17 | 2003-05-01 | Williams Robert O. | Topical compositions and methods for treating pain |
Cited By (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927634B2 (en) * | 2004-09-24 | 2011-04-19 | Sunny Biodiscovery, Inc. | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof |
US20100255069A1 (en) * | 2004-09-24 | 2010-10-07 | Sunny Biodiscovery, Inc. | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of angelica sinensis, and methods of preparation thereof |
US8388794B2 (en) | 2008-07-16 | 2013-03-05 | Nitto Denko Corporation | Process for producing adhesive patch |
CN101890079B (en) * | 2010-04-29 | 2014-08-06 | 贵阳春科药业技术研发有限公司 | Medical preparation for preventing and treating rhinitis and preparation method thereof |
CN101890079A (en) * | 2010-04-29 | 2010-11-24 | 贵阳春科药业技术研发有限公司 | Medical preparation for preventing and treating rhinitis and preparation method thereof |
US11451856B2 (en) | 2011-07-12 | 2022-09-20 | Snap Inc. | Providing visual content editing functions |
CN103127243A (en) * | 2011-11-22 | 2013-06-05 | 吉林省第二荣复军人医院 | Medicament for treating transaminase-increasing diseases caused by acute or chronic hepatitis and hepatic diseases |
US11734712B2 (en) | 2012-02-24 | 2023-08-22 | Foursquare Labs, Inc. | Attributing in-store visits to media consumption based on data collected from user devices |
US11625443B2 (en) | 2014-06-05 | 2023-04-11 | Snap Inc. | Web document enhancement |
US11317240B2 (en) | 2014-06-13 | 2022-04-26 | Snap Inc. | Geo-location based event gallery |
US11595569B2 (en) | 2014-07-07 | 2023-02-28 | Snap Inc. | Supplying content aware photo filters |
US11625755B1 (en) | 2014-09-16 | 2023-04-11 | Foursquare Labs, Inc. | Determining targeting information based on a predictive targeting model |
US11741136B2 (en) | 2014-09-18 | 2023-08-29 | Snap Inc. | Geolocation-based pictographs |
US11281701B2 (en) | 2014-09-18 | 2022-03-22 | Snap Inc. | Geolocation-based pictographs |
US11190679B2 (en) | 2014-11-12 | 2021-11-30 | Snap Inc. | Accessing media at a geographic location |
US11783862B2 (en) | 2014-12-19 | 2023-10-10 | Snap Inc. | Routing messages by message parameter |
US11372608B2 (en) | 2014-12-19 | 2022-06-28 | Snap Inc. | Gallery of messages from individuals with a shared interest |
US11250887B2 (en) | 2014-12-19 | 2022-02-15 | Snap Inc. | Routing messages by message parameter |
US11803345B2 (en) | 2014-12-19 | 2023-10-31 | Snap Inc. | Gallery of messages from individuals with a shared interest |
US11301960B2 (en) | 2015-01-09 | 2022-04-12 | Snap Inc. | Object recognition based image filters |
US11388226B1 (en) | 2015-01-13 | 2022-07-12 | Snap Inc. | Guided personal identity based actions |
US11662576B2 (en) | 2015-03-23 | 2023-05-30 | Snap Inc. | Reducing boot time and power consumption in displaying data content |
US11392633B2 (en) | 2015-05-05 | 2022-07-19 | Snap Inc. | Systems and methods for automated local story generation and curation |
US11449539B2 (en) | 2015-05-05 | 2022-09-20 | Snap Inc. | Automated local story generation and curation |
US11496544B2 (en) | 2015-05-05 | 2022-11-08 | Snap Inc. | Story and sub-story navigation |
US11315331B2 (en) | 2015-10-30 | 2022-04-26 | Snap Inc. | Image based tracking in augmented reality systems |
US11769307B2 (en) | 2015-10-30 | 2023-09-26 | Snap Inc. | Image based tracking in augmented reality systems |
US11380051B2 (en) | 2015-11-30 | 2022-07-05 | Snap Inc. | Image and point cloud based tracking and in augmented reality systems |
US11599241B2 (en) | 2015-11-30 | 2023-03-07 | Snap Inc. | Network resource location linking and visual content sharing |
US11611846B2 (en) | 2016-02-26 | 2023-03-21 | Snap Inc. | Generation, curation, and presentation of media collections |
US11631276B2 (en) | 2016-03-31 | 2023-04-18 | Snap Inc. | Automated avatar generation |
US20170366965A1 (en) * | 2016-06-21 | 2017-12-21 | Chiun Mai Communication Systems, Inc. | Communication device, communication system and method therefor |
US11843456B2 (en) | 2016-10-24 | 2023-12-12 | Snap Inc. | Generating and displaying customized avatars in media overlays |
US11750767B2 (en) | 2016-11-07 | 2023-09-05 | Snap Inc. | Selective identification and order of image modifiers |
US11397517B2 (en) | 2016-12-09 | 2022-07-26 | Snap Inc. | Customized media overlays |
US11616745B2 (en) | 2017-01-09 | 2023-03-28 | Snap Inc. | Contextual generation and selection of customized media content |
US11250075B1 (en) | 2017-02-17 | 2022-02-15 | Snap Inc. | Searching social media content |
US11720640B2 (en) | 2017-02-17 | 2023-08-08 | Snap Inc. | Searching social media content |
US11748579B2 (en) | 2017-02-20 | 2023-09-05 | Snap Inc. | Augmented reality speech balloon system |
US11189299B1 (en) | 2017-02-20 | 2021-11-30 | Snap Inc. | Augmented reality speech balloon system |
US11670057B2 (en) | 2017-03-06 | 2023-06-06 | Snap Inc. | Virtual vision system |
US11258749B2 (en) | 2017-03-09 | 2022-02-22 | Snap Inc. | Restricted group content collection |
US11558678B2 (en) | 2017-03-27 | 2023-01-17 | Snap Inc. | Generating a stitched data stream |
US11297399B1 (en) | 2017-03-27 | 2022-04-05 | Snap Inc. | Generating a stitched data stream |
US11349796B2 (en) | 2017-03-27 | 2022-05-31 | Snap Inc. | Generating a stitched data stream |
US11195018B1 (en) | 2017-04-20 | 2021-12-07 | Snap Inc. | Augmented reality typography personalization system |
US11451956B1 (en) | 2017-04-27 | 2022-09-20 | Snap Inc. | Location privacy management on map-based social media platforms |
US11409407B2 (en) | 2017-04-27 | 2022-08-09 | Snap Inc. | Map-based graphical user interface indicating geospatial activity metrics |
US11385763B2 (en) | 2017-04-27 | 2022-07-12 | Snap Inc. | Map-based graphical user interface indicating geospatial activity metrics |
US11474663B2 (en) | 2017-04-27 | 2022-10-18 | Snap Inc. | Location-based search mechanism in a graphical user interface |
US11392264B1 (en) | 2017-04-27 | 2022-07-19 | Snap Inc. | Map-based graphical user interface for multi-type social media galleries |
US11782574B2 (en) | 2017-04-27 | 2023-10-10 | Snap Inc. | Map-based graphical user interface indicating geospatial activity metrics |
US11556221B2 (en) | 2017-04-27 | 2023-01-17 | Snap Inc. | Friend location sharing mechanism for social media platforms |
US11418906B2 (en) | 2017-04-27 | 2022-08-16 | Snap Inc. | Selective location-based identity communication |
US11675831B2 (en) | 2017-05-31 | 2023-06-13 | Snap Inc. | Geolocation based playlists |
US11721080B2 (en) | 2017-09-15 | 2023-08-08 | Snap Inc. | Augmented reality system |
US11335067B2 (en) | 2017-09-15 | 2022-05-17 | Snap Inc. | Augmented reality system |
US11617056B2 (en) | 2017-10-09 | 2023-03-28 | Snap Inc. | Context sensitive presentation of content |
US11558327B2 (en) | 2017-12-01 | 2023-01-17 | Snap Inc. | Dynamic media overlay with smart widget |
US11265273B1 (en) | 2017-12-01 | 2022-03-01 | Snap, Inc. | Dynamic media overlay with smart widget |
CN107875370B (en) * | 2017-12-19 | 2020-12-29 | 深圳健安医药有限公司 | Traditional Chinese medicine composition for promoting enterokinesia to exhaust and preventing intestinal adhesion and preparation method thereof |
CN107875370A (en) * | 2017-12-19 | 2018-04-06 | 深圳健安医药有限公司 | For promoting enterocinesia exhaust to prevent the Chinese medicine composition and preparation method of intestinal adhesion |
US11487794B2 (en) | 2018-01-03 | 2022-11-01 | Snap Inc. | Tag distribution visualization system |
US11507614B1 (en) | 2018-02-13 | 2022-11-22 | Snap Inc. | Icon based tagging |
US11523159B2 (en) | 2018-02-28 | 2022-12-06 | Snap Inc. | Generating media content items based on location information |
US11722837B2 (en) | 2018-03-06 | 2023-08-08 | Snap Inc. | Geo-fence selection system |
US11491393B2 (en) | 2018-03-14 | 2022-11-08 | Snap Inc. | Generating collectible items based on location information |
US11297463B2 (en) | 2018-04-18 | 2022-04-05 | Snap Inc. | Visitation tracking system |
US11683657B2 (en) | 2018-04-18 | 2023-06-20 | Snap Inc. | Visitation tracking system |
US11670026B2 (en) | 2018-07-24 | 2023-06-06 | Snap Inc. | Conditional modification of augmented reality object |
US11676319B2 (en) | 2018-08-31 | 2023-06-13 | Snap Inc. | Augmented reality anthropomorphtzation system |
US11450050B2 (en) | 2018-08-31 | 2022-09-20 | Snap Inc. | Augmented reality anthropomorphization system |
US11704005B2 (en) | 2018-09-28 | 2023-07-18 | Snap Inc. | Collaborative achievement interface |
US11812335B2 (en) | 2018-11-30 | 2023-11-07 | Snap Inc. | Position service to determine relative position to map features |
US11558709B2 (en) | 2018-11-30 | 2023-01-17 | Snap Inc. | Position service to determine relative position to map features |
US11698722B2 (en) | 2018-11-30 | 2023-07-11 | Snap Inc. | Generating customized avatars based on location information |
US11199957B1 (en) | 2018-11-30 | 2021-12-14 | Snap Inc. | Generating customized avatars based on location information |
CN109342636A (en) * | 2018-12-03 | 2019-02-15 | 国药集团新疆制药有限公司 | A kind of FUFANG XUELIAN JIAONANG identification method |
US11751015B2 (en) | 2019-01-16 | 2023-09-05 | Snap Inc. | Location-based context information sharing in a messaging system |
US11294936B1 (en) | 2019-01-30 | 2022-04-05 | Snap Inc. | Adaptive spatial density based clustering |
US11693887B2 (en) | 2019-01-30 | 2023-07-04 | Snap Inc. | Adaptive spatial density based clustering |
US11500525B2 (en) | 2019-02-25 | 2022-11-15 | Snap Inc. | Custom media overlay system |
US11574431B2 (en) | 2019-02-26 | 2023-02-07 | Snap Inc. | Avatar based on weather |
US11249614B2 (en) | 2019-03-28 | 2022-02-15 | Snap Inc. | Generating personalized map interface with enhanced icons |
US11606755B2 (en) | 2019-05-30 | 2023-03-14 | Snap Inc. | Wearable device location systems architecture |
US11785549B2 (en) | 2019-05-30 | 2023-10-10 | Snap Inc. | Wearable device location systems |
US11206615B2 (en) | 2019-05-30 | 2021-12-21 | Snap Inc. | Wearable device location systems |
US11714535B2 (en) | 2019-07-11 | 2023-08-01 | Snap Inc. | Edge gesture interface with smart interactions |
US11218838B2 (en) | 2019-10-31 | 2022-01-04 | Snap Inc. | Focused map-based context information surfacing |
US11128715B1 (en) | 2019-12-30 | 2021-09-21 | Snap Inc. | Physical friend proximity in chat |
US11429618B2 (en) | 2019-12-30 | 2022-08-30 | Snap Inc. | Surfacing augmented reality objects |
US11343323B2 (en) | 2019-12-31 | 2022-05-24 | Snap Inc. | Augmented reality objects registry |
US11228551B1 (en) | 2020-02-12 | 2022-01-18 | Snap Inc. | Multiple gateway message exchange |
US11765117B2 (en) | 2020-03-05 | 2023-09-19 | Snap Inc. | Storing data based on device location |
US11776256B2 (en) | 2020-03-27 | 2023-10-03 | Snap Inc. | Shared augmented reality system |
US11290851B2 (en) | 2020-06-15 | 2022-03-29 | Snap Inc. | Location sharing using offline and online objects |
US11314776B2 (en) | 2020-06-15 | 2022-04-26 | Snap Inc. | Location sharing using friend list versions |
US11503432B2 (en) | 2020-06-15 | 2022-11-15 | Snap Inc. | Scalable real-time location sharing framework |
US11601888B2 (en) | 2021-03-29 | 2023-03-07 | Snap Inc. | Determining location using multi-source geolocation data |
US11606756B2 (en) | 2021-03-29 | 2023-03-14 | Snap Inc. | Scheduling requests for location data |
Also Published As
Publication number | Publication date |
---|---|
US7645462B2 (en) | 2010-01-12 |
CN1494901A (en) | 2004-05-12 |
US20040043062A1 (en) | 2004-03-04 |
CN1214785C (en) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7645462B2 (en) | Acupoint patch | |
CN102293874B (en) | Multifunctional medicinal pillow and preparation method thereof | |
CN101810685B (en) | Chinese medicinal composition for treating gonitis and preparation method thereof | |
CN105233010A (en) | Wine capable of invigorating kidney and strengthening Yang and making method thereof | |
CN103393591A (en) | Deodorant enzyme body wash | |
CN101301459B (en) | Medicated pillow | |
CN107496585A (en) | It is a kind of that there is warming kidney and enhancing body, the lavipeditum pack of bowl spares function of invigorating spleen | |
CN102068680B (en) | Omphaloidean external medicament for treating enteritis and preparation method thereof | |
CN102846872B (en) | Traditional Chinese medicine for treating facial paralysis and preparation method thereof | |
CN103961569A (en) | Foot bath medicine bag | |
CN106860718A (en) | A kind of lavipeditum powder and preparation method thereof | |
CN102058841B (en) | Medicine for umbilicus external use for treating hypertension and preparation method thereof | |
CN102058862B (en) | Externally applied medicament for pediatric umbilical part and preparation method thereof | |
CN102973687B (en) | Oral liquid for regulating female hormonal balance | |
CN106552039A (en) | It is a kind of to cure root bone pain footbath with traditional Chinese medicines health care prescription | |
CN110538288A (en) | Intelligent system plaster for conditioning physique and preventing and treating diseases and preparation method thereof | |
CN109674974A (en) | One kind, which invigorates the kidney and stops nocturnal emission, supports first plaster and preparation method thereof | |
CN103610848A (en) | Traditional Chinese medicine for treating cerebral thrombosis | |
CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
CN102579757B (en) | Anti-aging Chinese medicine composition in separation medicine and moxibustion umbilicus mode | |
CN102018936A (en) | Umbilically applied drug for treating gynaopathy and preparation method thereof | |
CN104510774A (en) | Nymphaea tetragona medicinal moxibustion | |
CN101244207B (en) | Traditional Chinese medicament for treating cardiovascular and cerebrovascular diseases with tongue bottom blood-letting acupuncture drug administration | |
CN112107560A (en) | Intelligent system plaster for conditioning physique and preventing and treating various facial paralysis diseases and preparation method | |
RU2357748C1 (en) | Multiactive bath extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |